Innovation Centers

Nurturing the global innovation ecosystem

Learn more

About us

We seek the best science and technology, no matter where it is, to solve the greatest unmet needs of our time.

Through our four regional Innovation Centers—located in Boston, California, London and Asia Pacific—we catalyze, support and invest in highly differentiated early-stage innovations that extend and improve lives everywhere. 

Transformative  

A great idea can come from anywhere. That’s why Johnson & Johnson has established Innovation Centers in the world’s top life science hubs, which are constantly percolating with new concepts for improving human health. With each collaboration, our expert teams in Boston, California, London and Asia Pacific nurture the global innovation ecosystem to ensure its continued vibrancy.

Each Innovation Center is designed to identify the best science and technology in the region, so we can create thriving collaborations with entrepreneurs and scientists developing important pharmaceuticals, medical device technologies and consumer healthcare products.

An integrated team of scientific and business experts is onsite at each of our four centers, with flexible deal-making capabilities to meet the needs of any company.

Our teams bring a history of success in R&D, product development and commercialization to each conversation; they know how to advance transformative technologies into products that change lives.

Leadership

  • Robert Urban
    Global Head, Johnson & Johnson Innovation
  • Rowan Chapman
    Head, Johnson & Johnson Innovation, California
  • Richard Mason
    Head, Johnson & Johnson Innovation, London
  • Dong Wu
    Head, Johnson & Johnson Innovation, Asia Pacific
  • Close

    Robert Urban,
    PhD

    Global Head, Johnson & Johnson Innovation

    Robert is Head of the Johnson & Johnson Innovation, Boston. He joined the Johnson & Johnson Family of Companies from the Massachusetts Institute of Technology, where he was the founding Executive Director of the Koch Institute for Integrative Cancer Research. In this role, Robert worked to build the Koch Institute into a new standard for interdisciplinary disease-focused research via an expanding, highly-effective, relationship network with other academic oncology centers, industrial partners, cancer-focused philanthropists and investors. During Robert’s tenure, the Koch Institute launched 17 start-up companies and its technology was the source of more than 50 out-licensing transactions.

    Robert was recruited to MIT from Acretia Inc. – a product acquisition and out-licensing company where he was the President and CEO. During his time at Acretia Inc. the organization conducted technical due diligence on more than 280 product opportunities and completed the acquisition of three distinct product lines.

    Prior to this, Robert held a variety of business development and clinical development roles in the pharmaceutical industry. He has worked in the areas of oncology, HPV, anti-inflammatory and infectious diseases. His experience includes clinical product development, operations oversight, licensing and acquisitions, capital fund raising, company creation, and building relationships with key thought-leaders.

    Robert received his Bachelor of Arts degree in Microbiology and his PhD in Microbiology and Immunology from the University of Texas system, and was an Irvington Fellow in structural immunology at Harvard University.

  • Close

    Rowan Chapman,
    PhD

    Head, Johnson & Johnson Innovation, California

    Rowan is the Head of Johnson & Johnson Innovation, California. Rowan will lead the California team to build upon recent successes and manage a portfolio of co-investments spanning across all three sectors of Johnson & Johnson. 

    Rowan will expand her strong external networks within the innovation ecosystem and continue our efforts to identify the most promising transformational science and technology in the Pharmaceutical, Medical Device and Consumer sectors and seek to bring them into Johnson & Johnson Family of Companies. 

    Rowan and team will develop and strengthen models to leverage collaboration through flexible deal structures and investments. She will oversee sourcing, transactional and partnerships co-management activities and will leverage her unique expertise as a part of the Johnson & Johnson Innovation Leadership Team. 

    She brings with her a strong expertise and passion for building new companies, end to end digital solutions and data analytics. Rowan most recently served as Head of Healthcare Investing, GE Ventures. There she led the team responsible for GE Ventures’ healthcare investing strategy and portfolio as well as managing partnerships and thought leadership with a particular focus on digital health, data analytics and precision medicine. In this role she drove creation of the first three Healthcare “NewCos” incubated and launched from GE. 

    Prior to joining the ventures team, Rowan served as Head of Precision Diagnostics at GE Healthcare, where she was responsible for strategy development to integrate lab services, products, data, informatics, software, and content. Before GE, she spent 11 years as a Partner at Mohr Davidow Ventures, where she drove development of the life science investment strategy and practice area. Her investments ranged from therapeutics to diagnostic to digital. 

    Prior to venture capital, Rowan was a very early employee at Rosetta Inpharmatics, a healthcare data analytics company, where she executed multiple business development and partnering deals ranging from strategic to revenue generating for the company. Rowan was previously a Product Marketing Manager at Incyte Genomics where she was responsible for spearheading statistical analytics for the expression product lines as well as development of business and marketing plans for the first bacterial microarray. 

    Rowan holds a Ph.D. and first class honors degree in Biochemistry from Cambridge University, U.K. and was a post-doctoral fellow at the University of California, San Francisco. She has been involved on community projects and has a passion to make an impact on diversity. 

    Rowan lives near SFO airport with 5 chickens, 3 children and her husband.

  • Close

    Richard Mason

    Head, Johnson & Johnson Innovation, London

    Richard is the head of Johnson & Johnson Innovation, London. He joins Johnson & Johnson Innovation from XO1 Limited, where he served as CEO until the company was acquired by Janssen in March 2015.

    Prior to his role at XO1, Richard was Head of Strategy and Business Development at specialist pharmaceutical and medical device company BTG Plc, where he led its transformation into a leading interventional medicine company through multiple acquisitions.

    Richard also served as an Executive-in-Residence for Advent Venture Partners LLC where he was a turnaround CEO for several portfolio companies. Previously he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT).

    Richard trained in medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree in immunology from UCL and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management and teaches the MBA elective in biotechnology and pharmaceuticals.

    Richard resides near Cambridge, UK. In his spare time Richard enjoys skiing, running, flying and sailing.

  • Close

    Dong Wu

    Head, Johnson & Johnson Innovation, Asia Pacific

    Dong is Head of Johnson & Johnson Innovation, Asia Pacific. He joined the Innovation team from Johnson & Johnson’s Consumer business where he was Vice President of R&D, responsible for the Global Engineering Organization and leading the transformation of the emerging markets R&D groups. In that role, he led the exploration of new product opportunities for Johnson & Johnson in global markets.

    Dong joined Johnson & Johnson in 2007 as Senior Director, Head of Emerging Markets R&D where he focused on developing personal care products for emerging markets. During this time, he facilitated programs aimed at developing high value products and driving a culture of innovation.

    Prior to joining Johnson & Johnson, Dong worked at Unilever where he held various positions in Quality Assurance, Manufacturing and Research & Development. Dong became part of the team that founded the Unilever Regional Innovation Center in Shanghai, where he was acting head of the Development Laboratory. He then became Manufacturing General Manager and Site General Manager of the Hefei plant, Unilever’s largest manufacturing site worldwide. During his career at Unilever, he worked in China, the UK, the U.S. and Japan.

    Dong has a Bachelor’s degree in Applied Chemistry from Fudan University and an MBA from China Europe International Business School.

Team Members

  • Robert Urban
    Global Head, Johnson & Johnson Innovation
  • Rowan Chapman
    Head, Johnson & Johnson Innovation, California
  • Richard Mason
    Head of Johnson & Johnson Innovation, London
  • Dong Wu
    Head, Johnson & Johnson Innovation, Asia Pacific
  • Lilian Alcaraz
    New Ventures and Transaction Lead, Neuroscience
  • Sahar Ali
    Office Leader
  • Amir Babaei-Mahani
    Senior Director, New Ventures, Medical Devices
  • Ibraheem Badejo
    Senior Director, New Ventures
  • Tatyana Beldock
    Senior Director, New Ventures
  • Jacqueline Benson
    Vice President, Immunology Scientific Innovation
  • Jeanne Bolger
    Vice President, Venture Investments
  • Kara Bortone
    Director, Venture Sourcing & Development
  • David Brush
    Senior Director, Transactions
  • Fabian Buller
    Director, New Ventures
  • Jeff Calcagno
    New Ventures
  • Sylvaine Cases
    Vice President, Oncology Scientific Innovation
  • Parth Chakrabarti
    Senior Director, Transactions
  • William E. Cohn
    Vice President
  • Renee Compton Ryan
    Vice President, Venture Investments
  • Karin Conde-Knape
    Vice President, Cardiovascular & Metabolism Scientific Innovation
  • Kathy Connell
    Director, New Ventures
  • Ann Connolly
    Senior Director, New Ventures
  • Lily Cortese
    Director, Transactions & Business Analytics
  • Rick Davis
    Senior Director, New ventures and Transactions, Oncology
  • Cris De Luca
    Director, Digital Health New Ventures
  • Dana Deardorff
    Senior Director of New Ventures
  • Stefanie Dhanda
    Senior Director, Consumer Scientific Innovation
  • Sanjeev Dutta
    Vice President, Medical Devices
  • Michael Elliott
    Vice President, Immunology Scientific Innovation
  • Stacy Feld
    Vice President of Consumer Venture Investments and External Innovation
  • Elena Fernandez-Kleinlein
    Senior Director, Consumer Scientific Innovation
  • Michael Flaschen
    Vice President, Transactions
  • Ryan Flinn
    Innovation Integration Communication Leader for the Americas
  • Yiu-Lian Fong
    Diagnostics Innovation Lead
  • Mann Fung
    Vice President, Oncology Scientific Innovation
  • Anthony Gemmell
    Senior Director, Transactions
  • Anna Gran
    New Ventures Lead, Nordics
  • Elva Guan
    Office Manager
  • Thomas Gustafson
    Vice President, Cardiovascular & Metabolic Scientific Innovation
  • Jennifer Hamilton
    Senior Director, New Ventures
  • Stefan Hart
    Director, New Ventures Singapore and India
  • Kurt Hertogs
    Platform Innovation & Incubation Strategy Leader
  • Chelsea Hewitt
    Global Innovation Activation Leader
  • Beth Hill
    Senior Director, Platform Innovation
  • Madelaine Holden
    Innovation Activation Specialist
  • Iqbal Hussain
    Senior Counsel
  • John Isaac
    Senior Director, Neuroscience External Innovation
  • Declan Jones
    Vice President, Neuroscience Scientific Innovation
  • Louise Jopling
    Director of Immunology Scientific Innovation
  • V. Kadir Kadhiresan
    Vice President, Venture Investments
  • Yelda Kaya
    Senior Director, Transactions
  • Alan Koder
    Director of Operations - Boston, MA
  • Emma Kohring
    Communications Leader
  • Jun Kusunoki
    Director, New Ventures Japan
  • Nicola La Monica
    Senior Director, Infectious Diseases and Vaccines Scientific Innovation
  • Christopher Lalli
    Communications
  • Han Li
    Partnership Manager
  • Tess Li
    Finance Director
  • Suzan Liao
    Senior Director, Portfolio Management and Business Operations
  • Samantha Lifson
    Innovation Activation Specialist
  • Bo Liu
    Principal, Venture Investments, JJDC
  • Thomas Luby
    Senior Director, New Ventures
  • Mirren Mandalia
    Senior Director, New Ventures & Transactions, Medical Devices
  • Tyrone Mao
    Site Leader of Emerging Markets
  • Thorsten Melcher
    Senior Director, New Ventures
  • Anthony Milinowicz
    Director Digital Innovation
  • Laurent Morlet
    Director, Digital Health New Ventures
  • Nick Mourlas
    Senior Director, New Ventures
  • Widya Mulyasasmita
    Manager, New Ventures
  • Vijay Murthy
    Principal, Venture Investments
  • Marian Nakada
    Vice President, Venture Investments
  • Shakti Narayan
    Vice President,Transactions
  • Kuldeep Neote
    Senior Director, New Ventures
  • Jeffrey S. Nye
    Vice President Neuroscience Innovation and Scientific Partnership Strategy
  • Scott Orchard
    Senior Counsel
  • Sonal Patel
    VP, Oncology Scientific Innovation
  • Charles R. Bridges
    Vice President, Therapeutic Area Expert, CV
  • Robert Radinsky
    Vice President, Scientific Innovation
  • Melinda Richter
    Head of JLABS, Johnson & Johnson Innovation
  • Stephanie Robertson
    Director, New Ventures
  • Bruce R. Rosengard
    Chief Medical Science and Technology Officer
  • Giridhar Sathiamoorthy
    Director of Business Operations and Project Management
  • Eric Schaeffer
    Senior Director, Neuroscience Innovation
  • Nerida Scott
    Senior Director, Transactions
  • Guy Seabrook
    Vice President, Neuroscience Innovation
  • Nikie Shi
    Director, Transactions
  • Kenny Simmen
    Vice President, Infectious Diseases and Vaccines Scientific Innovation
  • Peter Stebbins
    Transactions Lead, Medical Devices
  • Lesley Stolz
    Head of JLABS California
  • Jim Tobin
    Vice President, Cardiovascular & Metabolic Scientific Innovation
  • Sanjay Vinaik
    Senior Director, Business Operations & Program Management
  • Erin Washington
    Manager, Transactions & Business Analytics
  • Stuart Wilks
    Assistant General Counsel
  • Eric Wu
    Senior Counsel
  • Asish K. Xavier
    Vice President, Venture Investments
  • Mingde Xia
    Senior Director, New Ventures
  • Hong Xin
    Director, New Ventures Greater China and Korea
  • Rebecca Yu
    Head of JLABS @ Toronto
  • Wei Zang
    IT Lead
  • Biao Zheng
    Vice President, Immunology Scientific Innovation
  • Larry Zhy
    Senior Director, Transactions
  • Carolyne Zimmermann
    Senior Director of Transactions
  • Close

    Robert Urban,
    PhD

    Global Head, Johnson & Johnson Innovation

    Robert is Head of the Johnson & Johnson Innovation, Boston. He joined the Johnson & Johnson Family of Companies from the Massachusetts Institute of Technology, where he was the founding Executive Director of the Koch Institute for Integrative Cancer Research. In this role, Robert worked to build the Koch Institute into a new standard for interdisciplinary disease-focused research via an expanding, highly-effective, relationship network with other academic oncology centers, industrial partners, cancer-focused philanthropists and investors. During Robert’s tenure, the Koch Institute launched 17 start-up companies and its technology was the source of more than 50 out-licensing transactions.

    Robert was recruited to MIT from Acretia Inc. – a product acquisition and out-licensing company where he was the President and CEO. During his time at Acretia Inc. the organization conducted technical due diligence on more than 280 product opportunities and completed the acquisition of three distinct product lines.

    Prior to this, Robert held a variety of business development and clinical development roles in the pharmaceutical industry. He has worked in the areas of oncology, HPV, anti-inflammatory and infectious diseases. His experience includes clinical product development, operations oversight, licensing and acquisitions, capital fund raising, company creation, and building relationships with key thought-leaders.

    Robert received his Bachelor of Arts degree in Microbiology and his PhD in Microbiology and Immunology from the University of Texas system, and was an Irvington Fellow in structural immunology at Harvard University.

  • Close

    Rowan Chapman,
    PhD

    Head, Johnson & Johnson Innovation, California

    Rowan is the Head of Johnson & Johnson Innovation, California. Rowan will lead the California team to build upon recent successes and manage a portfolio of co-investments spanning across all three sectors of Johnson & Johnson. 

    Rowan will expand her strong external networks within the innovation ecosystem and continue our efforts to identify the most promising transformational science and technology in the Pharmaceutical, Medical Device and Consumer sectors and seek to bring them into Johnson & Johnson Family of Companies. 

    Rowan and team will develop and strengthen models to leverage collaboration through flexible deal structures and investments. She will oversee sourcing, transactional and partnerships co-management activities and will leverage her unique expertise as a part of the Johnson & Johnson Innovation Leadership Team. 

    She brings with her a strong expertise and passion for building new companies, end to end digital solutions and data analytics. Rowan most recently served as Head of Healthcare Investing, GE Ventures. There she led the team responsible for GE Ventures’ healthcare investing strategy and portfolio as well as managing partnerships and thought leadership with a particular focus on digital health, data analytics and precision medicine. In this role she drove creation of the first three Healthcare “NewCos” incubated and launched from GE. 

    Prior to joining the ventures team, Rowan served as Head of Precision Diagnostics at GE Healthcare, where she was responsible for strategy development to integrate lab services, products, data, informatics, software, and content. Before GE, she spent 11 years as a Partner at Mohr Davidow Ventures, where she drove development of the life science investment strategy and practice area. Her investments ranged from therapeutics to diagnostic to digital. 

    Prior to venture capital, Rowan was a very early employee at Rosetta Inpharmatics, a healthcare data analytics company, where she executed multiple business development and partnering deals ranging from strategic to revenue generating for the company. Rowan was previously a Product Marketing Manager at Incyte Genomics where she was responsible for spearheading statistical analytics for the expression product lines as well as development of business and marketing plans for the first bacterial microarray. 

    Rowan holds a Ph.D. and first class honors degree in Biochemistry from Cambridge University, U.K. and was a post-doctoral fellow at the University of California, San Francisco. She has been involved on community projects and has a passion to make an impact on diversity. 

    Rowan lives near SFO airport with 5 chickens, 3 children and her husband.

  • Close

    Richard Mason,
    M.D., MBA

    Head of Johnson & Johnson Innovation, London

    Richard is the head of Johnson & Johnson Innovation, London. He joins Johnson & Johnson Innovation from XO1 Limited, where he served as CEO until the company was acquired by Janssen in March 2015.

    Prior to his role at XO1, Richard was Head of Strategy and Business Development at specialist pharmaceutical and medical device company BTG Plc, where he led its transformation into a leading interventional medicine company through multiple acquisitions. 

    Richard also served as an Executive-in-Residence for Advent Venture Partners LLC where he was a turnaround CEO for several portfolio companies. Previously he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT).

    Richard trained in medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree in immunology from UCL and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management and teaches the MBA elective in biotechnology and pharmaceuticals.

    Richard resides near Cambridge, UK. In his spare time Richard enjoys skiing, running, flying and sailing. 

  • Close

    Dong Wu

    Head, Johnson & Johnson Innovation, Asia Pacific

    Dong is Head of Johnson & Johnson Innovation, Asia Pacific. He joined the Innovation team from Johnson & Johnson’s Consumer business where he was Vice President of R&D, responsible for the Global Engineering Organization and leading the transformation of the emerging markets R&D groups. In that role, he led the exploration of new product opportunities for Johnson & Johnson in global markets.

    Dong joined Johnson & Johnson in 2007 as Senior Director, Head of Emerging Markets R&D where he focused on developing personal care products for emerging markets. During this time, he facilitated programs aimed at developing high value products and driving a culture of innovation.

    Prior to joining Johnson & Johnson, Dong worked at Unilever where he held various positions in Quality Assurance, Manufacturing and Research & Development. Dong became part of the team that founded the Unilever Regional Innovation Center in Shanghai, where he was acting head of the Development Laboratory. He then became Manufacturing General Manager and Site General Manager of the Hefei plant, Unilever’s largest manufacturing site worldwide. During his career at Unilever, he worked in China, the UK, the U.S. and Japan.

    Dong has a Bachelor’s degree in Applied Chemistry from Fudan University and an MBA from China Europe International Business School.

  • Close

    Lilian Alcaraz

    New Ventures and Transaction Lead, Neuroscience

    Lilian is the Medicinal Chemistry Lead, for Johnson & Johnson Innovation, London

    Lilian has over 16 years’ experience in Medicinal Chemistry gained through working in both large pharma and CRO environments. Before joining Johnson & Johnson Innovation, Lilian was Senior Director of Chemistry at Charles River (Argenta). In this role, he co-headed of the chemistry department and was the Collaboration Leader of a large multidisciplinary tri-party partnership overseeing the delivery of multiple drug discovery projects. Prior to that, Lilian spent 13 years at AstraZeneca advancing in various leadership roles culminating as a Principal Scientist. During his time at AstraZeneca, Lilian gained extensive experience in lead optimization, lead identification and library design and synthesis. He was a member of the milestone review group for Respiratory and Inflammation research area and led improvement projects aimed at enhancing strategic component of Candidate Drug Discovery.

    Lilian received his postgraduate degree in Molecular and Supramolecular Organic Chemistry and his Ph.D. in Organic Chemistry from Louis Pasteur University. He was a Post-Doctoral Fellow at the University of York. Over the years, he has been involved in the successful delivery of nine clinical candidates, 3 of which are still in clinical evaluation. Lilian is the author and co-author of 71 publications and patents, and of a book on Medicinal Chemistry.  

  • Close

    Sahar Ali

    Office Leader

    Sahar Ali grew up in Houston, TX. She is fascinated by the minute details of life forms, and therefore, obtained her Bachelor of Science degree in Biology from Sam Houston State University. After temperamental bacteria and chemical bonds drove her crazy, she decided to minor in criminal justice where she had the chance of visiting a state prison.

    Professionally, she has over six years of customer service experience in the healthcare industry. She has met and enjoyed working with people from all walks of life from crying toddlers to the screaming elderly, and not to forget the eccentric physicians. She had the opportunity to work face to face with patients as a physical therapy assistant, as well as work behind the scenes with billing, insurance companies, and various other departments.

    One of her accomplishments was to serve on a team of super users to implement a new software system for an entire clinic of 40 physician offices.

    During her free time, she likes to read, do yoga, attend local art festivals, and try different cuisines.

  • Close

    Amir Babaei-Mahani

    Senior Director, New Ventures, Medical Devices

    Amir is Senior Director, New Ventures, Medical Devices based in the Johnson & Johnson Innovation Centre in London.

    Amir has a wealth of experience implementing efficiency strategies, assessing business development opportunities and developing and implementing go-to-market models for healthcare organizations. Before joining Johnson & Johnson, Amir was a Senior Engagement Manager and Leader at McKinsey & Company.

    Amir trained as an Orthopaedic Surgeon at Kings and University College in London, and has held various surgical posts at Guy’s and St Thomas’ Hospital, St Bartholomew’s Hospital and The Royal London Hospital. He holds Membership of the Royal College of Surgeons and maintains an active and inquisitive role in Orthopaedic surgery.
     

  • Close

    Ibraheem Badejo,
    PhD

    Senior Director, New Ventures

    Ibraheem (Ib) is Senior Director, New Ventures at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector.

    From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University.

    During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired.

    Ib received his BA degree in chemistry from Avila University.  He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending.

  • Close

    Tatyana Beldock

    Senior Director, New Ventures

    Tatyana is Senior Director, New Ventures, at Johnson & Johnson Innovation, California.  She focuses on sourcing and catalyzing innovation opportunities across all healthcare sectors, with a focus on consumer and medical devices.   Tatyana brings nearly two decades of diverse experience spanning all healthcare sectors and a track record of success as a venture capital investor, business development professional, entrepreneur, and investment research analyst. 

    Previously, Tatyana founded and ran an investment advisory company, FireRock Advisors, to source and evaluate investments in healthcare innovation for private equity, venture capital and family office clients.  As an entrepreneur, she founded and became CEO of a consumer healthcare company, Slim & Sage, featured on Good Morning America, in The New York Times, and Marie Claire.  Prior to that, she was a Principal at Technology Partners, where she helped source or fund consumer health, medical device, and biopharma venture investments that subsequently created realized shareholder value of over $2B. Earlier, Tatyana held strategy and business development positions at Johnson & Johnson and at Pfizer.  Tatyana began her career as a financial analyst for Salomon Smith Barney and as a medical devices investment research associate at JP Morgan, H&Q.  She also worked at the US Department of Health & Human Services.

    Tatyana earned a B.S. with honors from Carnegie Mellon University, and an MBA from the Harvard Business School, where she and her team won the HBS Business Plan Contest.

  • Close

    Jacqueline Benson,
    PhD

    Vice President, Immunology Scientific Innovation


    Jackie is Vice President, Immunology Scientific Innovation at Johnson & Johnson Innovation, California.  Jackie is responsible for creating and implementing an external innovation plan focused on developing an industry-leading portfolio of Immunology investment opportunities on the West Coast.  
     
    In addition, Jackie continues to serve as Estrela Venture Leader, Janssen Incubator, advancing innovative treatments for systemic lupus erythematosus (SLE).  Since Estrela launched in 2013, Jackie has led the Estrela Venture to a number of key milestones, including the declaration of two new molecular entities, one of which recently achieved first patient dosed in SLE patients. 
     
    Jackie joined the Janssen Pharmaceutical Companies of Johnson & Johnson as a Senior Research Scientist in 2001, playing an instrumental role in the research and discovery of several flagship programs, including STELARA® (ustekinumab) and guselkumab.  
     
    She received her B.S. in Biology from The Ohio State University, followed by her Ph.D. in Immunology from the College of Medicine at The Ohio State University, and was awarded a National Multiple Sclerosis Society postdoctoral fellowship at Stanford University School of Medicine.

  • Close

    Jeanne Bolger,
    MB BCh

    Vice President, Venture Investments

    Jeanne joined Johnson & Johnson Development Corporation (JJDC) as Vice President, Venture Investments, in February 2013.  She is based in London, UK at the Johnson & Johnson Innovation Centre. Jeanne’s responsibilities are focused on investing in and managing portfolio investments in the pharmaceuticals and biotechnology areas in Europe.

    Jeanne has over 25 years of pharmaceutical industry experience in management roles across R+D, Commercial and Business Development.  She spent 11 years in Licensing and Acquisition, most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined the Johnson & Johnson Family of Companies in 2005 from the Business Development group at GSK.

    In 2009, Jeanne became VP Alliance Management and Board Director at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan on immunotherapies targeting beta amyloid for Alzheimer’s disease.

    Jeanne received her medical degree from University College Dublin.  She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA).  She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI).  She has served as the sole pharmaceutical industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres.  She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland.

  • Close

    Kara Bortone,
    PhD

    Director, Venture Sourcing & Development

    As Head of Company Sourcing for JLABS, Kara leads the company recruitment and selection process for JLABS including JLABS San Diego, JLABS@QB3 in San Francisco and JLABS@LabCentral in Cambridge/Boston. In this role, Kara is actively building a pipeline of prospects and driving licensee companies through diligence, selection, and joining JLABS. Kara coordinates with the J&J Innovation Centers and J&J Development Corporation to build opportunities and grow relationships between JLABS companies and potential strategic partners.

    Kara joins Janssen R&D through Prescience International, where she was Director of Corporate Ventures, primarily focusing on the JLABS project. She has over 10 years experience in the European and the U.S. biotech sector. Prior to joining Prescience, Kara led the scientific communications and marketing for Belgian-based Galapagos NV at a period when the company grew from 60 to over 800 employees and completed its initial public offering on Euronext. She holds a BS in Chemistry from the University of North Carolina and a PhD in Biochemistry from the University of Texas.

  • Close

    David Brush,
    MS, MBA

    Senior Director, Transactions

    David is Senior Director of Transactions at the Johnson & Johnson Innovation, Boston. He has over twenty years of business development experience on both the buy and sell side, with global pharmaceutical, specialty and start-up companies.

    Previously, David was Senior Director of External Projects for the New Opportunities group at AstraZeneca. Prior to that he was VP of Business Development & Strategic Planning for CPEX Pharmaceuticals form 2007-2010, VP of Business Development of N. America for BTG International from 2003-2007. Prior to that, he held various positions in corporate development and licensing at Aventis Behring LLC, Small Molecule Therapeutics (start-up) , SmithKline, Astra Merck, Bristol-Myers Squibb and Damon Biotech.

    David received his MBA from the University of Michigan, a MS in Biochemistry from Michigan State University and a BS in Chemistry from the University of Michigan.

  • Close

    Fabian Buller,
    PhD

    Director, New Ventures

    Fabian is Director of New Ventures at Johnson & Johnson Innovation. Fabian is based in Zurich, Switzerland, and affiliated with Covagen AG, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

    Before joining the Johnson & Johnson family, Fabian was Director of Business Development at Covagen, a company acquired by Janssen in August 2014. In this role, he helped grow a successful biotech company and was instrumental in entering a strategic research & licensing partnership and ultimately, in the sale of the company. Prior to this, Fabian led immuno-oncology discovery research at Covagen with a focus on multi-specific protein therapeutics. Fabian brings in-depth knowledge on novel technologies for small molecule discovery through his academic research at ETH Zurich.

    Fabian received his Diploma degree in Chemistry from the University of Münster and studied at the Max-Planck Institute for Molecular Physiology in Dortmund and at University of California in Santa Barbara. Fabian holds a PhD degree from the Institute of Chemistry and Applied Biosciences at ETH Zurich.

  • Close

    Jeff Calcagno,
    MD

    New Ventures

    Jeff is on the New Ventures team at Johnson & Johnson Innovation, California.  Jeff joined the Johnson & Johnson Family of Companies in February 2011 and helped to establish the California Innovation Center.  He also worked for 18 months making and managing venture investments for Johnson & Johnson.  A licensed physician, he has over two decades of diversified healthcare and business experience: as a senior operating executive, business development professional, venture investor, entrepreneur, and clinician.

    Jeff began his business career as a management consultant at McKinsey & Company.  He later served as a healthcare research analyst at JP Morgan Hambrecht & Quist.  As an entrepreneur, he ran corporate development and operations for WIDCOMM, a technology company acquired by Broadcom, and served as CFO & CBO for Vela Pharmaceuticals, a venture-backed drug development company.  From 2006 to 2010 he was a Principal & Kauffman Fellow at Scale Venture Partners, a venture fund with over $1B under management.

    Jeff graduated Phi Beta Kappa in Biology from Harvard College and earned an M.D. from Harvard Medical School, where he was a Rotary International Ambassadorial Scholar.  He completed his medical-psychiatric internship and psychiatry residency at UCLA’s Neuropsychiatric Institute and served as program chief resident.  Afterwards, he was awarded and completed a clinical neuropharmacology fellowship focusing on the care of treatment-refractory patients.

  • Close

    Sylvaine Cases

    Vice President, Oncology Scientific Innovation

    Sylvaine has significant experience in the fields of cancer biology and metabolism, with more than 16 years in research and drug discovery in both pharma and biotech.  Most recently, she served as Senior Director in the Global Business Development Group and Head of External Science & Partnering, US West for Sanofi where she managed the US West Team’s biotech deal flow in alignment with the Sanofi R&D therapeutic areas.  In this role, she sourced, built and managed alliances with academic centers in the US West ecosystem.  Previous roles include Director of Pharmacology at Arete Therapeutics and Senior Group Leader at Cytokinetics where she led programs in cancer pharmacology and translational oncology. Prior to her move to biotech, Sylvaine held an academic appointment at the Gladstone Institutes at UCSF where she focused her research on metabolism and cancer with an emphasis on the tumor microenvironment.

    Sylvaine has a Ph.D. in Molecular Oncology from the Institut Gustave Roussy for Cancer Research in Villejuif France / University of Paris VII, France, and a Masters in Bioengineering, Major in Biochemistry from AgroParisTech (National Institute of Agronomy, Paris, France).  She spent her post-doctoral years at the at the Gladstone Institutes/UCSF and additionally holds a Sanofi Business Master Certificate from the London Business School.   She lives in the San Francisco Bay Area and enjoys its running trails, its gastronomy (both tasting and cooking!) and has a passion for literature.

     

  • Close

    Parth Chakrabarti,
    MBA

    Senior Director, Transactions

    Parth is Senior Director of Transactions at Johnson & Johnson Innovation, Boston. During his 15 years in the healthcare industry, Parth has been passionate about innovation in science and in business/transaction models. 

    Before joining Johnson & Johnson Innovation, Parth was a Director at Baxter BioScience where he helped build two new business units focused on oncology and specialty immunology entirely through licensing and external partnerships. Prior to that, he led the establishment of 'Innovation Cell' at Becton Dickinson & Co. that successfully established new growth strategy for its Medical Surgical Systems business unit. He and his team then successfully executed the strategy through a combination of acquisitions and partnership agreements to build a new business franchise. Before Becton Dickinson, Parth was an Investment manager at VenturEast Capital, one of the few pure-play healthcare focused venture funds based in India that specialize in cross-border company creation through early stage equity investment. 

    Before transitioning to the business side of healthcare, Parth spent 10 years as a scientist, most of it at Amgen Inc. working on variety of targets likes G-protein coupled receptor agonists and P-38 Kinase inhibitors as well as in a range of therapeutic areas like neuropathic pain, breast cancer & Alzheimer's disease. His research contributed to advancement of three candidates to clinical development.

    Parth is an inventor in 23 granted patents and has co-authored multiple peer-reviewed papers that have garnered more than 450 citations. He has a Master's degree in Healthcare Management from Harvard University, MBA from ISB, M. Pharm. (Medicinal Chemistry) from Indian Institute of Technology and a B. Pharm. from Nagpur University.

  • Close

    William E. Cohn,
    MD

    Vice President

    Dr. William E. “Billy” Cohn is the Vice President for Johnson &Johnson Medical Devices Companies and the Director of the new Center for Device Innovation at the Texas Medical Center in Houston. Dr. Cohn has a passion for medical device development and has more than 90 US patents granted or pending for his medical innovations that have provided the core technology for six venture-backed medical start-ups.

     

    A noted cardiovascular surgeon, Dr. Cohn is also a visionary serial inventor. He is a Professor of Surgery at Baylor College of Medicine and an Adjunct Professor of Bioengineering at both Rice University and the University of Houston.  His major research interests have been focused on decreasing the invasiveness of medical procedures in a wide variety of fields.

     

    Prior to joining Johnson & Johnson, Dr. Cohn was Director of the Center for Technology and Innovation and Director of the legendary Cullen Cardiovascular Research Laboratory at the Texas Heart Institute in Houston.  He has been intimately involved in the development of the continuous-flow, totally implantable, artificial heart.  In 2011, Dr. Cohn and Dr. O. H. Frazier successfully implanted the first pulseless total heart replacement device in a human patient. 

     

    His numerous awards include an honorary doctorate in science from Oberlin College, the Distinguished Scientist Award, given by the MacDonald Fund, and the Edison Award for excellence in human-centered design and innovation for the SentreHEART® Lariat®.  In 2000, Dr. Cohn was named the distinguished Inventor of the Year by the U.S. Intellectual Property Owners Association.  In 2014 he was named Outstanding Inventor of the Year by the Houston IPO.  In addition, in 2014 he received the Innovation award at ICI in Tel Aviv for inventing the TVA everLINQ system for percutaneous AV fistula creation and for founding TVA Medical.  In 2015, he was awarded a Lifetime Achievement Award for healthcare innovation by the Houston Technology Center.  Lastly, before joining J&J, he was a Venture Partner at Santé Ventures and was the Chief Medical Officer for BiVACOR USA and for Reliant Heart.

     

    After obtaining an undergraduate degree in Biology and Chemistry from Oberlin College in Ohio, Billy went on to receive his Doctor of Medicine from the Baylor College of Medicine in Houston, Texas.  He then completed seven years of general surgical and cardiothoracic surgical training at the Baylor College of Medicine Affiliated Hospitals and a one-year cardiothoracic fellowship at Boston’s Beth Israel Hospital. After completion of his training, he stayed on as a staff Cardiothoracic surgeon at the Beth Israel Deaconess Medical Center and as a full-time faculty of Harvard Medical School for ten years before being recruited back to his hometown of Houston.

  • Close

    Renee Compton Ryan

    Vice President, Venture Investments

    Renee is Vice President of Investments at the Johnson & Johnson Development Corporation, and is based at the Johnson & Johnson Innovation Center in California. Renee supports the investments for our Medical Devices and Diagnostics businesses and is a passionate supporter of medical innovation.

    Formerly, Renee was a Managing Director at Baird in Palo Alto, CA overseeing the medical device investment banking practice.  Prior to Baird, Renee oversaw the build out of the West Coast healthcare investment banking practice at Jefferies & Co.  In total, Renee has approximately 20 years of healthcare investment banking experience at firms such as Goldman Sachs and Credit Suisse.  She has structured over $15 Billion of transactions during this time including M&A, venture financing and public offerings of debt and equity.

    Renee earned her B.A. in economics at Georgetown University in Washington, D.C., and an MBA from Columbia University.

  • Close

    Karin Conde-Knape,
    PhD

    Vice President, Cardiovascular & Metabolism Scientific Innovation

    Karin Conde-Knape is Vice President of Cardiovascular & Metabolic Scientific Innovation at Johnson & Johnson Innovation, London.

    Previously, Karin was Global Head of Discovery in the CVM DTA at Roche where she was responsible for all the Early Research efforts as well as the Translational Biomarker and experimental medicine group.  While at Roche, Karin was directly or indirectly responsible for identifying and managing numerous external collaborations with well renowned institutions worldwide. In addition, throughout her career at Roche, she had several roles, including laboratory head, project leader, head of pharmacology and co-department head in the CV and Metabolism Disease and Translational Area, both in the US and in Switzerland.  She was responsible for setting and implementing the pharmacology strategy for the portfolio in the CVM group in areas such as Diabetes, Atherosclerosis, Dyslipidemia, Kidney, and CV disease.

    Karin received her PhD in Nutritional Sciences from the University of Connecticut, and completed her post-doctoral fellowship at Columbia University. 

  • Close

    Kathy Connell

    Director, New Ventures

    Kathy is Director of New Ventures, Australia and New Zealand (ANZ) for Johnson & Johnson Innovation, Asia-Pacific and is responsible for implementing our strategy across Australia and New Zealand.

    Kathy has a clinical background and started her commercial career as the VP of Global Business Development for an Australian biotechnology company. Prior to joining Janssen, Kathy worked for Sanofi engaged in in-licensing late stage pharmaceutical assets.  Kathy joined Janssen as Biotechnology Alliance Manager in 2011.

    Kathy is a registered psychologist and holds Post Graduate Diplomas in Health and Medical Law from the University of Melbourne, Psychology from Monash University and Bachelor degrees in Psychology (Swinburne University) and Applied Science from LaTrobe University.  She is based in Sydney Australia.  

  • Close

    Ann Connolly,
    PhD

    Senior Director, New Ventures

    Ann is Senior Director of New Ventures at Johnson & Johnson Innovation, London.

    Previously, Ann was the Senior Director Business Development with UCB Pharma, where she was responsible for business development activities supporting both Immunology and CNS divisions with their early stages of development.

    Ann was also the Director of Worldwide Business Development at GSK, and supported the Respiratory franchise to complement the existing R&D portfolio, as well as supporting device licensing activities. She also has experience in Preclinical Development and was involved in progressing many programs across therapeutic sectors for SmithKline Beecham/GSK.

    Ann holds a PhD in Biochemical Toxicology from the University of Surrey. 

  • Close

    Lily Cortese

    Director, Transactions & Business Analytics

    Lily is responsible for developing and executing transactions with our diverse industry partners, including biotech companies, venture capital, non-profit organizations, governments, and academic institutions regionally to access innovation across J&J’s areas of interest - our pharmaceutical Therapeutic Areas, Consumer and Medical Device Businesses. 

    She manages all aspects of the deal process, developing value-creating deal structures, leading term sheet & contract negotiations and driving the business case development & approval process. Lily also provides business and commercial analytics capabilities to the Boston IC team. 

    Previously, Lily held the position of Director, Business Operations and Project Management for three and a half years at the J&J Innovation Center in London and was a founding member of the team there. Prior to joining J&J she held various roles in Business Development in both the US and UK at Huntingdon Life Sciences, now Envigo. 

    Lily holds an MBA from the University of Cambridge, Judge Business School and a BA in psychology from William Paterson University.

  • Close

    Rick Davis

    Senior Director, New ventures and Transactions, Oncology

    Rick is Senior Director, New Ventures and Transactions, Oncology at Johnson & Johnson Innovation, London .  In this role, Rick leverages his experience and knowledge of the scientific and biotech landscape to identify and evaluate external opportunities and deliver transformative innovation into the pipeline.
     
    Rick has over 17 years of experience in the life sciences sector. Before joining Johnson & Johnson he was the Chief Executive Officer of a European clinical stage biotech company, Trino Therapeutics. Previously, he held a number of key positions at the Wellcome Trust. He was responsible for maximising financial returns on direct healthcare investments in both private and public equities and venture capital funds in their Investment Division.  During this time he was on the board of directors of a number of biotech companies and worked closely with management teams on strategy, financing and exits via M&A and public listings.
     
    Prior to this role, Rick was in Business Development where he established and managed a large corporate venture fund, building an extensive external pipeline of preclinical pharmaceutical assets sourced from EU and US academic and biotech labs. After a obtaining a PhD in pharmacology, he started his career in the biotechnology industry at Pharmagene where he helped to establish their therapeutics division and led multi-disciplinary teams in drug development and contract research.

  • Close

    Cris De Luca,
    MS

    Director, Digital Health New Ventures

    Cris is the Director Digital Health New Ventures at Johnson & Johnson Innovation, Boston where he is responsible for external healthcare technology innovation strategy and new ventures.

    Cris was previously Associate Director at Novartis Institutes for BioMedical Research where he led a Research Informatics organization building social computing and emerging technology programs. In 2010, Cris Co-Founded the largest startup venture pitch competition in the U.S. called Ultra Light Startups, accelerating hundreds of bootstrapping entrepreneurs in New England, New York, and Silicon Valley. 

    Cris was recognized by the Boston Business Journal as a 40 Under 40 game changer and an honoree of MedTech Boston’s 40 Under 40 Healthcare Innovators line-up.  

    He holds a Bachelor of Science in Business Administration from Suffolk University and a Master of Science in Computer Information Systems from Boston University. 

  • Close

    Dana Deardorff,
    PhD

    Senior Director of New Ventures

    Dana is Senior Director of New Ventures at Johnson & Johnson Innovation, Boston.  His focus is on developing and investing in new opportunities of strategic interest across the medical device sector.  

    Dana has over 20 years of experience in the medtech industry in various roles bridging technology and business.  Previously he worked for Covidien in several leadership positions including VP of Strategy & Portfolio Management, Advanced Technology, and Business Development.  Dana has also been an entrepreneur, starting multiple companies as a co-founder and leading early-stage technology and product development activities.  Most recently he served as an Entrepreneur-in-Residence and advisor to the University of Illinois, helping to evaluate and accelerate the commercial potential of innovative technologies.

    Dr. Deardorff has a joint doctorate in biomedical engineering from the University of California, Berkeley and University of California, San Francisco, and a bachelor’s degree in physics from Illinois Wesleyan University.

  • Close

    Stefanie Dhanda

    Senior Director, Consumer Scientific Innovation

    Stefanie is Senior Director of Consumer Scientific Innovation at Johnson & Johnson Innovation, Boston.  Stefanie leads Consumer sector efforts to grow and maintain a portfolio of innovative external partnerships, collaborations and investments for the benefit of J&J's Consumer businesses, which currently reach across broad and diverse sectors such as oral care, compromised skin, baby and maternal health, personal care and beauty, an OTC platform anchored in pain relief, cough/cold, and digestive health, as well as digital health platforms.

    Previously, Stefanie was a Managing Director at Stonebridge Associates, a Boston-based investment banking firm that she helped found in 1996. She has over 20 years of experience in providing strategic and financial advisory services to small and midsized family-owned and growth companies in the consumer and healthcare sectors.  Within that role she led mergers and acquisitions engagements, raised capital, defined business and financial strategy, performed complex due diligence and negotiated strategic alliances. In addition, Stefanie was independently consulting with several innovative startup and early-stage companies focused on the nutrition, health and wellness sector. Prior to Stonebridge, she worked at the Bank of New York.

    Stefanie has a Bachelor of Science degree in Finance and Operations & Strategic Management from Boston College.

  • Close

    Sanjeev Dutta,
    MD, MBA

    Vice President, Medical Devices

    Sanjeev is Vice President, Medical Devices at Johnson & Johnson Innovation, California.  He joins the Medical Science and Technology Team as the Therapeutic Area Expert for Robotics and Minimally Invasive Surgery.   

    Prior to joining Johnson & Johnson, Dr. Dutta was Associate Professor of Surgery at Stanford University School of Medicine and an attending surgeon at Lucile Packard Children’s Hospital at Stanford. He has nearly two decades of experience as a healthcare provider and is recognized as a leader in multispecialty minimally invasive surgery, with extensive experience in advanced laparoscopic, thoracoscopic, and robotic procedures.

    Sanjeev developed a number of “scarless” procedures that together embody a surgical approach called Stealth Surgery. He co-directed an FDA-funded lab (called MISTRAL) in collaboration with the Robotics & Medical Device Division of SRI International that focused on the development of disruptive medical technologies. He has published extensively in the areas of minimally invasive surgery, robotic surgery, surgical innovation, and surgical education, and is co-inventor on a number of medical device patents.

    Sanjeev received his MD degree from the University of Calgary in Canada. He trained in Abdominal & Thoracic Surgery at Dalhousie University, followed by fellowship training in Minimally Invasive & Robotic Surgery at McMaster University, and Neonatal & Pediatric Surgery at the Hospital for Sick Children in Toronto. He is a fellow of the American College of Surgeons, the Royal College of Surgeons of Canada, and the American Academy of Pediatrics. Sanjeev also holds a graduate degree in Educational Psychology from the University of Illinois and an MBA from the Stanford Graduate School of Business.

  • Close

    Michael Elliott,
    MBBS, PhD

    Vice President, Immunology Scientific Innovation

    Michael is Vice President of Immunology Scientific Innovation at Johnson & Johnson Innovation, Boston.  He has spent much of his career in the biotech and pharmaceutical industry, working in large and small companies.

    Michael’s career wtih the Johnson & Johnson Family of Companies includes 7 years at Centocor, where he led the clinical development of Centocor’s monoclonal antibody (mAb) products in immune and inflammatory disorders.  Foremost amongst these were the development and regulatory approval of the anti-TNF mAb infliximab (Remicade®) in rheumatoid arthritis, Crohn’s disease, ulcerative colitis and other inflammatory indications, and of the follow-on anti-TNF mAb, golimumab (Simponi®) in a range of rheumatic diseases.  His group also led clinical development of the first-in-class anti-IL-12/23 mAb, ustekinumab (Stelara®) for the treatment of psoriasis.

    More recently, Michael served as General Manager and Site Head at TransForm Pharmaceuticals, a Johnson & Johnson company focused on high throughput drug formulation, and was a member of the Johnson & Johnson Corporate Office of Science and Technology.  In January 2012, he transitioned to the role of Janssen Entrepreneur in Residence at Polaris Partners, a Boston-based VC firm, where he managed a co-investment relationship aiming to build a portfolio of investments in early stage pharma and biotech companies.

    Michael earned his medical degree (MBBS) and PhD from the University of Adelaide, Australia, and is a Fellow of the Royal Australasian College of Physicians. Michael has authored many peer-reviewed journal articles, reviews and book chapters in the field of cytokine immunology and protein therapeutics.

  • Close

    Stacy Feld

    Vice President of Consumer Venture Investments and External Innovation

    Stacy is Vice President of Consumer Venture Investments and External Innovation with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and is based in California.  

    Stacy leads consumer and health technology venture investing and is responsible for all equity investments across the Consumer global franchises, as well as enterprise areas that include Health and Wellness Solutions and Health Technology.   

    Stacy has nearly two decades of diverse experience in the healthcare, life sciences and consumer sectors as a transactional attorney, business development executive, venture investor and business strategist.

    Previously, Stacy was a partner at Physic Ventures, a venture capital firm investing in health and sustainability, where she led investments in personalized health solutions that empower consumers to improve their health and wellbeing.  Stacy has also been active in the design and execution of science-enabled innovation strategies, business incubation and spin-off opportunities, advising senior management of global enterprises in the CPG industry, as well as pre-commercial and commercial-stage companies in the personalized health and medical technology sectors. 

    Prior to joining Physic Ventures, Stacy held leadership positions in the business development groups at Genentech and Third Wave Technologies and was a technology transactions attorney at Wilson, Sonsini, Goodrich & Rosati.  Stacy serves as an advisor on the Springboard Enterprises Life Sciences Council and to the UCSF Clinical and Translational Research Institute T1 Catalyst Program.

    Stacy earned her B.A. in Sociology from the University of Pennsylvania and received her J.D. from Vanderbilt Law School.

  • Close

    Elena Fernandez-Kleinlein

    Senior Director, Consumer Scientific Innovation

    Elena is the Senior Director Consumer Scientific Innovation at Johnson & Johnson Innovation, London.

    Prior to this role, Elena was the Senior Director of R&D Global Topical Health Care for Johnson & Johnson Consumer & Personal Products. In this post, she was responsible for seeking innovative products and claims pipelines within the franchise and oversaw the product development program for iconic brands such as Band-Aid Adhesive Bandages, Johnson & Johnson’s Red Cross and other regional brands like Compeed, Neosporin and Bengay.

    Elena has grown in the Johnson & Johnson Family of Companies, previously holding roles of Senior Director R&D EMEA Topical Health, performing as the Worldwide Director Women’s Health R&D, and Manager Baby & Kids R&D EMEA for Johnson & Johnson in Germany. These positions have provided her an in-depth knowledge in Research & Development across different groups as well as launch & commercialization experience of different product categories. She has filed several patents.

    Elena holds a BS and MS in Food Science & Technology from Technical University Munich, Germany.

  • Close

    Michael Flaschen

    Vice President, Transactions

    Michael is the Vice President, Transactions for Johnson & Johnson Innovation, Asia-Pacific.  Michael’s team leads transactions for the region.  Previously, Michael was the head of transactions at Johnson & Johnson Innovation, California.  He has extensive experience structuring and negotiating pharma and biotech collaborations.
     
    Prior to joining Johnson & Johnson, Michael was a transactions lead for Amgen in Thousand Oaks, California.   At Amgen, Michael worked on a number of licenses, collaborations and acquisitions, first as a lawyer and later as a member of the External Innovation and Corporate Development teams.  Prior to Amgen, Michael worked on technology transactions in the New York and London offices of Kirkland & Ellis, an international law firm.
     
    Michael earned a BA in philosophy at Tulane University in New Orleans, and a JD from New York University.

  • Close

    Ryan Flinn

    Innovation Integration Communication Leader for the Americas

    Ryan Flinn is Innovation Integration Communication Leader for the Americas at Johnson & Johnson Innovation. As a former journalist with more than a decade of experience covering a wide range of topics and industries, he brings a deep understanding of what drives news coverage, what appeals to reporters and editors and how to create and shape a compelling story.

     

    Prior to joining J&J in June 2016, he was a director of earned media for W2O Group in San Francisco, a communications agency, where he helped healthcare clients with a range of needs, including clinical trial news, crisis communications, regulatory interactions and initial public offerings. He joined the W2O Group in June 2013 from Bloomberg News, where he served as the West Coast biotech reporter, covering drug development, clinical trials, FDA approvals, health care policy, emerging treatment trends, medical conferences and corporate financial developments.

     

    Ryan has a BA in Classics from the College of the Holy Cross.

  • Close

    Yiu-Lian Fong,
    PhD, MBA

    Diagnostics Innovation Lead

    Yiu-Lian is the Innovation Lead for Diagnostics, at Johnson & Johnson Innovation, London.

    Prior to joining Johnson & Johnson Innovation, Yiu-Lian was Divisional Vice President for R&D at Abbott Molecular. In this position, she was responsible for R&D strategic oversight, menu expansion, and the development of next generation molecular diagnostic platform technologies. Previously, she was the Executive Director of Molecular Diagnostics and Companion Diagnostics Development at Novartis Oncology. Yiu-Lian brings a broad and extensive background in the pharmaceutical and biotechnology industries including experience in technology and product development, blood testing/screening, vaccines and IVD Immuno and molecular diagnostics, as well as therapeutic drug/vaccine development. 

    Yiu-Lian received her M.S. in Life Sciences from The National Tsing Hua University in Taiwan, and her MBA from the University of Massachusetts, Amherst.  She earned her Ph.D. in Molecular Physiology and Biophysics from Vanderbilt University and was a post graduate fellow at Johns Hopkins University. Yiu-Lian also has 24 publications in Pper review journals and several issued patent applications. 

  • Close

    Mann Fung,
    MD, MBA

    Vice President, Oncology Scientific Innovation

    Mann Fung is Vice President, Oncology Scientific Innovation at Johnson & Johnson Innovation Centre, Asia Pacific.

    Previously, Mann was the Vice President, Compound Development Team Leader at Janssen. Mann was also the Executive Director/Head of Specialty Pharma Development at McNeil.  Prior to joining Johnson & Johnson, Mann was the Head of Oncology & Critical Care at Eli Lilly Japan and a Team Leader and Reviewer at the FDA.

    Mann has his Masters in Healthcare Management from Harvard, an Executive MBA from Indianapolis and his MD & BS in Pharmacy from the University of Utah.

  • Close

    Anthony Gemmell

    Senior Director, Transactions

    Anthony is Senior Director of Transactions for Johnson & Johnson Innovation, London.

    Previously, Anthony worked within several business development roles in Johnson & Johnson Pharmaceutical Group Business Development including New Business Development, Mergers & Acquisitions and New Ventures, and has completed a wide variety of business development, licensing, acquisition and divestment assignments.

    Prior to joining the Johnson & Johnson Family of Companies, Anthony had management roles in the UK and EMEA in New Product Development and Business Unit Management with Lilly, Servier and Bristol Myers Squibb spanning multiple disease areas. He started his career teaching Biological Sciences in secondary education.

    Anthony has degrees in Biological Sciences and Business Administration. 

  • Close

    Anna Gran,
    PhD MBA

    New Ventures Lead, Nordics

    Anna Gran is the External Innovation Liaison for the Nordics.

    Before this role, Anna was the Nordic Brand Manager for Oncology, based in Finland. In this position, she was responsible for integrating the hematology business into the Nordic Oncology team; as well as for the brand vision and strategy of two hematological cancer drugs, including leading the launch of a new drug in the Nordic region. Previously, she was Nordic Project Manager and Medical Advisor. In this role, she was responsible for medical projects and advisory throughout and after the launch of a new prostate cancer drug in Sweden, Norway, Finland and Denmark. Before Anna joined industry, she worked as a research scientist for 9 years in research teams in Finland and the Netherlands.

    Anna received her Master of Science and her PhD in Biochemistry from the University of Helsinki. She received her MBA in Business Administration from the University of Cambridge- Judge Business School. Anna is also the author of several peer-reviewed articles in international life science journals.  

  • Close

    Elva Guan,
    MBA

    Office Manager

    Elva Guan is the Office Manager at Johnson & Johnson Innovation Centre, Asia Pacific.

    Previously, Elva worked at IBM in the Global Business Services unit and lead business project communication & coordination, event management and government relationship maintenance to ensure effective, smooth cooperation externally and internally.  Prior to IBM, Elva worked with the Ministry of Commerce, National Development and Reform Commission on foreign investment and funding at the State Tax Bureau.

    Elva has her MBA from Shanghai University of Finance and Economics with a Business Management specialty.

  • Close

    Thomas Gustafson,
    PhD

    Vice President, Cardiovascular & Metabolic Scientific Innovation

    Gus is Vice President of Cardiovascular & Metabolic Scientific Innovation at Johnson & Johnson Innovation, California.  A biologist with an extensive background in diabetes and cardiovascular drug discovery, Gus is dedicated to finding better treatments, and ideally cures, for metabolic disease such as Type 2 diabetes which is reaching epidemic proportions throughout the world.

    Formerly, Gus was Site Lead at Merck where he led the Diabetes Department. Prior to Merck, he served as Vice President at Pfizer where he led the CVMED Target Exploratory Unit. Earlier in his career, Gus served as Chief Scientific Officer at Eli Lilly and led the Diabetes “Drug Hunting Team”.  Prior to this, Gus spent 9 years as VP at Metabolex, a Bay Area biotechnology company. Prior to industry, Gus enjoyed an academic career at the University of Maryland-Baltimore, publishing over 50 papers and achieving the rank of Associate Professor in the Department of Physiology.

    Gus earned his BS in biology at the University of Wisconsin – Stevens Point, and a PhD in Pharmacology and Toxicology at the University of Arizona in Tucson.   He was a postdoctoral scholar at Stanford University and at UC-San Francisco.

  • Close

    Jennifer Hamilton,
    PhD

    Senior Director, New Ventures

    Jennifer Hamilton is the Senior Director, New Ventures at Johnson & Johnson Innovation.
     
    Formerly, Jennifer was an Advisor to Johnson & Johnson Innovation where she was responsible for scouting opportunities in Canada.  Previously, Jennifer was an Advisor to Johnson & Johnson’s Corporate Office of Science and Technology (COSAT) where she maintained similar responsibilities.
     
    Prior to joining J&J, Jennifer spent 10 years as Venture Partner at UK-based Nomura Phase4 Ventures, an international life sciences fund.  Previously, she was an Investment Director with Rothschild Asset Management which managed two global publicly traded funds and lead investments in Angiotech, AnorMed, Immgenics, Inflazyme and TerraGen.  She has worked as an advisor to early and late-stage companies, venture funds and pension funds giving financing, business development and M&A advice.
     
    Jennifer has an MSc and a PhD in Experimental Pathology/Lipid Metabolism from the University of British Columbia and a BSc from the University of Guelph.

  • Close

    Stefan Hart

    Director, New Ventures Singapore and India

    Stefan is the Director of New ventures, Singapore and India at Johnson & Johnson Innovation, Asia-Pacific.

    Previously Stefan worked at Roche as the Manager of Pre-clinical Academic Alliance. In this role, he directed key external collaborations. Prior to that, Stephan was a Senior Scientist at S*BIO Pte Ltd. In this role, Stefan acted as a core member of Pracritinib drug development team. He led the pre-clinical development and successfully implemented the clinical biomarker strategy.

    Stefan trained as an engineer in biotechnology at the University for Applied Sciences Weihenstephan (Freising, Germany). He received his Ph.D. research at the Max-Planck-Institute for Biochemistry, where his work focused on the transactivation of the EGFR by G protein-coupled receptors in human cancer, and resulted in significant publications that led to the MPIB Junior Research Award in 2004. Stefan did his postdoctoral research at the Institute for Medical Biology (IMB), Singapore where he launched the Singapore OncoGenome Project. Stefan is also the author of 25 publications in peer reviewed scientific journals and of 2 patents.

  • Close

    Kurt Hertogs,
    PHD

    Platform Innovation & Incubation Strategy Leader

    Kurt Hertogs is currently Platform Innovation & Incubation Strategy Leader at the Johnson & Johnson Innovation Center in London. In this role, he is responsible for leading the implementation of the JLINX incubation initiative. He is working together with the JLINX management team and other stakeholders to identify transformative innovations and to provide entrepreneurs the opportunity to accelerate bringing their products to patients in need.

    Kurt started his professional career as a founding research director of Belgian biotech start-ups Tibotec and Virco and was involved in the discovery and pharmacological profiling of the anti-infective drugs Prezista, Intelence, Edurant, Incivo, Olysio and Sirturo, and the development of AntivirogramTM and VircoTypeTM diagnostic platforms. Today, these drugs are positively impacting and improving the lives of hundreds of thousands of HIV-, HCV-, or TB - infected people worldwide.

    After the acquisition of Tibotec-Virco NV by Johnson & Johnson in 2002 and prior to joining the London Innovation Center in 2013, Kurt led the European and Global Enabling Research Capabilities at Janssen R&D, helping to advance the discovery product portfolio across Janssen’s five strategic therapeutic areas.

    Kurt is a trained Pharmacist and holds a PhD in Pharmaceutical Sciences from the Catholic University of Leuven, Belgium.

    Email contact: khertog1@its.jnj.com

  • Close

    Chelsea Hewitt

    Global Innovation Activation Leader

    As Head of Marketing for JLABS, Chelsea leads the strategic marketing efforts, program develop and external activation for JLABS. In this role,Chelsea oversees the strategy and implementation of marketing initiatives including online and offline marketing, partnering, commercialization programs, industry presence and other activities to build a strong innovation network. Prior to joining JLABS, Chelsea was Director of Marketing and New Ventures at Prescience International where she led the strategic marketing, corporate partnerships and business development functions which included market expansion of Prescience solutions and partnering with key industry stakeholders including Johnson & Johnson, The National Cancer Institute, the National Institutes of Health Heart Lung and Blood Institute and UC Berkeley’s Center for Executive Development.

    Prior to Prescience, Chelsea was an analyst at a London-based investment firm providing diligence for investment strategies and prospective portfolio companies as well as for the development and assessment of internally generated projects in the company’s internal incubator, Illuminator Plc. She holds a BA from the University of California Santa Barbara.

  • Close

    Beth Hill

    Senior Director, Platform Innovation

    Beth is Senior Director of Platform Innovation at Johnson & Johnson Innovation, California.  She is an experienced pharmaceutical innovator with many years of strategic and operational leadership in creating and applying technologies that overcome technical and business barriers.

    Formerly with Janssen R&D, Beth led global cross-disciplinary functions working from late discovery through development and commercialization with a focus on drug delivery and drug+device combination products.

    Beth has also led R&D teams to develop therapeutics for cancer and autoimmune disease.  At Systemix /Novartis she held functional and project leadership roles in stem, somatic cell and gene therapies. She began her industrial career developing antibody-based diagnostics at Syva Co.

    Beth earned her BA in Medical Technology at Augustana College, her PhD in Microbiology at Columbia University, and completed her post-doctoral studies in the Stanford Department of Structural Biology.

  • Close

    Madelaine Holden

    Innovation Activation Specialist

    Madelaine is responsible for marketing and events for JLABS. Her role includes coordinating high-quality, diverse and distinctive programming ranging from one-on-one investor meetings, workshops and large panel series to networking and social events.

    Madelaine’s prior experiences working in the biotech industry include program management at Prescience International and CONNECT, an organization that catalyzes the creation of innovative technology and life sciences products in San Diego. Madelaine has a BA in Communications from the University of Washington. She currently sits on the steering committee for the Women In Bio (WIB) Southern California Chapter.

  • Close

    Iqbal Hussain

    Senior Counsel

    Iqbal is Senior Counsel at Johnson & Johnson Innovation Center, London where he is engaged in a full range of strategic transactions.

    Iqbal has a strong corporate law background, having previously worked as an Associate at Ropes & Gray in London. Prior to Ropes & Gray, he worked at Slaughter and May. Iqbal’s law firm experience included corporate secondments with Premier Foods, GlaxoSmithKline, and most recently, the Johnson & Johnson Innovation Center in London, where Iqbal has worked part-time since August 2013.

    Iqbal holds an LLB from the University of Sheffield and a postgraduate diploma from the Oxford Institute of Legal Practice. He is qualified as a solicitor in England and Wales.

  • Close

    John Isaac

    Senior Director, Neuroscience External Innovation

    John is Senior Director, Neuroscience External Innovation at Johnson & Johnson Innovation, London.  In this role John uses his drug discovery and scientific experience to identify and advance external opportunities in the areas of Alzheimer’s Disease and Mood Disorders.

    Prior to joining Johnson & Johnson, since November 2014, John was Head of Neuroscience and Mental Health at the Wellcome Trust.  Previous to that he worked at Eli Lilly and Company at their neuroscience research campus near London, UK.  At Lilly he led a team of labs dedicated to identifying new therapies for Alzheimer’s disease and schizophrenia.

    John’s scientific interests centre on synaptic mechanisms in circuit function, and how dysfunction causes psychiatric and neurological disease.  John obtained a BSc in Pharmacology and Biochemistry at the University of Southampton in 1990 and remained at Southampton for his graduate work, studying mechanisms of epilepsy with Prof Howard Wheal.

    In 1994 he joined Dr Robert Malenka’s laboratory at University of California San Francisco working on mechanisms of long-term synaptic plasticity in hippocampus and somatosensory cortex, also in close collaboration with Dr Roger Nicoll.  After completion of this post doc position, John joined Prof Graham Collingridge’s laboratory at the University of Bristol back in the UK in 1996, where he completed a one year post doc before establishing his own lab there. He rose up through the ranks to full Professor before leaving in 2004 to set up a lab at the Intramural Program at NINDS/NIH in Bethesda, MD, USA studying mechanisms and roles of synaptic plasticity in developing cortical circuits.

  • Close

    Declan Jones,
    PhD

    Vice President, Neuroscience Scientific Innovation

    Declan is Vice President of Neuroscience Scientific Innovation at Johnson & Johnson Innovation London.

    Declan previously worked for GlaxoSmithKline’s Centre of Excellence for External Drug Discovery (CEEDD) where he was responsible for creating scientific strategies and managing processes from preclinical to Phase II state programs across all therapeutic areas. Prior to CEEDD, he spent nearly 14 years in neuroscience drug discovery and development within GSK. Declan was the recipient of an R&D Pipeline award in 2009 for his leadership of a schizophrenia program with a successful Phase II outcome.

    Declan has over 75 peer reviewed publications and external presentations and served as core panel member for Neuroscience on the BBSRC grant committee for a 3 year term.  He received his PhD from the University of Bradford and did post-doctoral work at Emory University and University of Hertfordshire before joining the pharmaceutical industry.

  • Close

    Louise Jopling

    Director of Immunology Scientific Innovation

    Louise is Director of Immunology Scientific Innovation at the Johnson & Johnson Innovation Centre London.  Her main responsibilities are to apply the highest level of scientific expertise and insights to identify the best opportunities for value-generating collaborations, and support development of an industry-leading portfolio of investment opportunities across Europe.

    Prior to this Louise held a number of positions at Janssen in the Medical Affairs function with both UK and European responsibility within the Immunology Therapy Area.
     
    Louise joined Janssen in May 2008 following a successful research career in both academia and industry.  After completing her PhD in Immunology (Imperial College London), Louise undertook a post-doctoral fellowship at Harvard Medical School (Boston). From there Louise worked at Celltech/ UCB for 6 years as a senior pharmacologist, where she was responsible for developing and testing pre-clinical models of inflammatory disease, and was responsible for leading the psoriasis research strategy.

     

  • Close

    V. Kadir Kadhiresan,
    PhD

    Vice President, Venture Investments

    V. Kadir Kadhiresan, PhD, Vice President, Venture Investments, joined Johnson & Johnson Innovation - JJDC, Inc. (JJDC) in 2007. He serves on the boards of JJDC portfolio companies and is based in Boston, Massachusetts.

    Dr. Kadhiresan has more than a decade of operational experience in various functional roles including research, product development, and business development. Before joining JJDC, as head of Business Development at Guidant, Inc., now Boston Scientific, Inc., Dr. Kadhiresan led several transactions to access novel medical device technologies with venture investments, M&As, licensing and joint ventures. Prior to entering business development, he led the research and development of multiple early-stage technologies and products in cardiac rhythm management and heart failure.  Dr. Kadhiresan was instrumental in the development of the cardiac resynchronization therapy for heart failure, now a multi-billion dollar worldwide market. At Heart Rhythm Technologies, a subsidiary of Guidant, he led the development of an ablation technology for treatment of atrial fibrillation and raised venture financing for the project. In addition, Dr. Kadhiresan is an inventor on more than 40 patents and has published several articles in peer-reviewed journals.

    Dr. Kadhiresan received a PhD and Master of Science in Biomedical Engineering from the University of Michigan, Ann Arbor, a Master of Business Administration from the Kellogg School of Management at Northwestern University, and a Bachelor of Science in Electrical Engineering from National Institute of Technology (REC), Trichy, India.

  • Close

    Yelda Kaya,
    MD, JD, MBA

    Senior Director, Transactions

    Yelda is the Senior Director of Transactions in Johnson & Johnson Innovation Center, California.

    Leveraging a diverse career practising emergency medicine, corporate law and business development, Yelda brings extensive experience to transactions delivering a unique breadth of deals across sectors with an established track record of successfully leading, structuring, negotiating and executing complex deals over the last 10 years.

    Yelda joined the Johnson & Johnson family from GSK’s worldwide business development group. She holds a MBBS, LLB and MBA from the University of Melbourne.

  • Close

    Alan Koder

    Director of Operations - Boston, MA

    Alan is responsible for strategic operations for JLABS including the planning and execution of the program. He oversees the service delivery model to resident JLABS companies enabling a cost efficient environment for companies to progress their scientific work.

    Alan has over 10 years’ experience in the biotechnology and pharmaceutical industries where he has served in both scientific and operational capacities. Prior to joining JLABS, he led Operations and EH&S at Ambrx, Inc where he partnered with R&D and senior management to improve efficiencies and compliance. Previously, he held scientific positions at the Salk Institute and Novartis where he focused gene expression and new drug development to treat inflammatory, cardiovascular and metabolic diseases. Alan has a BS in Biochemistry and Cell Biology from the University of California, San Diego (UCSD) and is a member of Phi Beta Kappa. He is currently pursuing his MBA at the University of San Diego with an emphasis in Finance.

  • Close

    Emma Kohring

    Communications Leader

    Emma is Communications leader at Johnson & Johnson Innovation, London.  She has responsibility to foster new and deepen existing relationships in the science ecosystem to create extensive connectivity with key opinion leaders, academics, entrepreneurs, government officials, VC’s and other stakeholders. 

    Prior to joining Johnson & Johnson in late 2016, Emma held Innovation and Communications positions at Procter & Gamble (P&G), most recently in Global Homecare in Geneva, Switzerland and previously in Beauty Care  in London, UK.  Emma has over 20+ year experience in R&D and Scientific Communications where she successfully developed and delivered brand advocacy and enhanced reputational drivers.   

    During her career Emma has spent time in New Business Creation, leading external relations programs across the organisation, including building a communications strategy for the launch of two new Joint Venture (JV) technologies. She has significant consumer products experience, having spent majority of her career  as Scientific Communications Director at P&G’s Beauty & Grooming division. In this role she led integrated scientific communications for all brands targeting key influencers and professionals in the market, collaborating  with R&D to evolve outreach strategies and narratives. In this role she led integrated scientific communications for all brands targeting key influencers in the market and also collaborated with R&D to evolve outreach strategies and narratives in innovation.

    Emma received her BSc in Biochemistry from Birmingham University.  She is passionate about life sciences and telling relevant and compelling stories about new health & beauty innovations. 

  • Close

    Jun Kusunoki,
    PhD

    Director, New Ventures Japan

    Jun Kusunoki is the Director, New Ventures, the Innovation Center, Asia Pacific and is based in Tokyo. 

    Jun has over 23 years of experience as a drug discovery biologist focusing on diabetes, obesity, and dyslipidaemia. Previously, Jun was a Head of the lipid/ nutrient metabolism research group at Tsukuba Research Institute (Japan) of Merck Research Laboratories and the Director at MSD until 2008. He has held leadership positions in a number of pharmaceutical companies including MSD and Eli Lilly.

    During his career he advanced four compounds to preclinical/clinical development, and nine targets to key milestones such as compound library screening, portfolio entry, hit, lead, and/or candidate molecule identification.

    Jun received his B.S., M.Sci and Ph.D. degrees in Pharmaceutical Science from faculty of pharmaceutical Science at Hoshi University (Japan) and is a registered pharmacist in Japan. He did post-doctoral training at the Zena and Michael A. Wiener Cardiovascular Institute.

  • Close

    Nicola La Monica,
    PhD

    Senior Director, Infectious Diseases and Vaccines Scientific Innovation

    Nicola is Senior Director of Infectious Diseases and Vaccines Scientific Innovation at Johnson & Johnson Innovation, Boston.

    From 2009 to 2012, Nicola was at Idera Pharmaceuticals, where he was Vice President of biology.  From 1991 to 2009, he was the Director of Antiviral Research at the Istituto di Ricerche di Biologia Molecolare (IRBM), Rome, Italy, a research site of Merck Research Laboratories.  Prior to that, he held the positions of Director of Oncology and Director of Cancer Immunology and Genomics.

    During his career, Nicola has led drug discovery efforts for the treatment of Hepatitis C virus infections and oncology, as well as development programs for cancer immunotherapy.  Nicola earned his BA degree in Biology from the University of Rochester in 1982.  His graduate studies were completed at Columbia University, where he earned a PhD in Microbiology in 1988.

  • Close

    Christopher Lalli

    Communications

    Christopher is the Manager of Communications at Johnson & Johnson Innovation, California.  He also manages communications for JLABS and Janssen Healthcare Innovation (Care4Today).

    Previously, Christopher was a Director of Client Services at PR firms including Cohn & Wolfe, Fleischman-Hillard and UpStart Communications working on a variety of business-to-business, financial, healthcare, technology and consumer clients.. Christopher joined the Johnson & Johnson Family of Companies in 2014 to lead communications for Johnson & Johnson Innovation and Johnson & Johnson Innovation, JLABS and began his career in marketing at Xerox Corporation.

    Christopher studied pre-veterinary medicine at Cal Poly San Luis Obispo and earned his Bachelor of Arts in Economics from California State University, Long Beach.

  • Close

    Han Li,
    PhD

    Partnership Manager

    Han joined the New Ventures team at Johnson & Johnson Innovation, California to support the Center’s efforts in managing and optimizing relations with, and commitments to external partners.

    Previously, Han was part of the business development and alliance management team at the University of California, San Francisco, where she identified, built and maintained relationships with biotech/pharma industry, venture capitalists and academic centers. Prior to this, Han was a Competitive Intelligence Intern at Genentech, and before that, a consultant for QB3 New Ventures Consulting Group, where she worked with startup companies on developing business plans and conducting market analyses.

    Han received her B.S. in Biochemistry and Biomathematics from the University of Scranton, and her Ph.D. in Cell Biology from the University of California, San Francisco, where she was a NSF fellow.  Han conducted her postdoctoral work in oncology at Genentech. 

  • Close

    Tess Li

    Finance Director

    Tess Li is The Finance Director at Johnson & Johnson Innovation Centre, Asia Pacific.

    Previously, Tess worked at Johnson & Johnson Medical Taiwan and has also held finance roles in GE Healtcare and Johnson & Johnson Vision Care Taiwan/Hong Kong. 

    Tess graduated from the University of Houston, concentrated in Accounting, and held a Master degree of Business Administration.
     

  • Close

    Suzan Liao

    Senior Director, Portfolio Management and Business Operations

    Sue is the Senior Director of Portfolio Management and Business Operations at the California Innovation Center. In this role, she has responsibility for coordinating the operational management of the Innovation Center, including transactions and project reviews, as well as, day-to-day processes.

    In addition, she is also responsible for planning and executing a number of key infrastructure projects for a variety of internal stakeholders and external business partners, while working synergistically with her colleagues in the other centers.

    Prior to this role at Johnson & Johnson, Sue was the Head of R&D Clinical Business Operations at Medivation, at which she helped to build scalable processes and systems, streamline existing operations, develop key performance metrics, and budgets for all clinical programs.  Previously, she held positions of increasing responsibility at The Clorox Company, as the Global Head of Product Supply and Finance Operations, and at Gilead Sciences.  She has also held roles within J&J in IT at LifeScan and R&D Strategic Sourcing for J&J’s west coast pharmaceutical companies.  Additionally, her breadth of experience includes consulting, acquisition integration, global channel & product management, business development, sales operations, supply chain, business process outsourcing, and systems development for the US Department of Defense and telecommunications industries.

    Sue holds a Bachelor of Arts degree from the University of California at Berkeley and a MBA from the Wharton School at the University of Pennsylvania. 

  • Close

    Samantha Lifson

    Innovation Activation Specialist

    Samantha is the Marketing and Events Manager with Johnson & Johnson Innovation, JLABS, working out of the Boston Innovation Center. Sammy is responsible for event planning and digital marketing on the East Coast. Her role includes coordinating high-quality, diverse and distinctive programming ranging from one-on-one investor meetings, workshops and large panel series to networking and social events.

    Prior to joining JLABS, Sammy served as the Community & Online Organizing Coordinator at Planned Parenthood Hudson Peconic, assisting with communications, government relations, and social media advocacy. She holds a B.A. in Advertising and Women’s & Gender Studies from Syracuse University.

  • Close

    Bo Liu,
    PhD, MBA

    Principal, Venture Investments, JJDC

    Bo joined Johnson & Johnson Development Corporation (JJDC) in January 2013. He is based in China and focuses on the life science investment opportunities in Asia Pacific regions.

    Prior to joining JJDC, Bo was Director of Business Development and Strategic Planning with GlaxoSmithKline Consumer Healthcare China, where he led key strategic initiatives in mergers and acquisitions, licensing and portfolio optimization. Prior to GSK, he worked in the corporate development and strategy group with Charles River Laboratories in Boston, where he played an instrumental role in several strategic transactions. Bo has executed M&A and licensing transactions in the US, Europe and Asia with total considerations over $2 billion.

    Bo received a PhD in Pharmacology from University of Rochester, an MBA from the University of Chicago, and a Master of Medicine from the seven-year program of Tongji Medical University in Wuhan, China. He received residency training in Urology at Union Hospital of Tongji Medical University. 

  • Close

    Thomas Luby,
    PhD

    Senior Director, New Ventures

    Tom is Senior Director of New Ventures at Johnson & Johnson Innovation, Boston.  He focuses primarily on cardiovascular & metabolic; infectious diseases and Vaccines; and neurobiology.

    Prior to joining the Johnson & Johnson Family of Companies, Tom was the Sr. Director of Research Ventures at Shire Human Genetic Therapies.  In this position, Tom played a central role in the evaluation, diligence, and deal processes across a number of successful early-stage investments in the rare disease space.  He was member of the BOD at Armagen Technologies, led the collaboration with Nimbus Discovery, and was instrumental in establishing and leading the alliance that Shire put in place with Atlas Venture.

    Prior to this, Tom held a variety of research and development roles in both start-up and mid-sized biotech.  He has worked on multiple discovery through Phase II programs in infectious disease, oncology, immunotherapy, and monogenetic disorders.  His experience includes pre-clinical development, early-stage portfolio oversight, licensing, due diligence, company formation, alliance management, and key opinion leader outreach. 

    Tom received his BS in Biology from State University of New York, his PhD in Immunology from Tufts University, and was a post-doctoral fellow in yeast genetics at Harvard School of Public Health.

  • Close

    Mirren Mandalia,
    MD MBA

    Senior Director, New Ventures & Transactions, Medical Devices

    Mirren is Senior Director of New Ventures & Transactions, Medical Devices at Johnson & Johnson Innovation, London. He leads identification and transactions of innovative early stage medical devices, to support Johnson & Johnson across Europe, Middle East and Africa.

    He joined Johnson & Johnson in 2013 leading a number of programmes leveraging innovative digital platforms to empower patients, improve clinical workflows & patient outcomes across a variety of clinical specialties. Prior to this role he was a member of the healthcare practice at The Boston Consulting Group in London, advising pharma, medtech, payers and providers on key strategic issues including business development, growth strategies and sales & marketing. Over the past few years, he has also been an advisor for a number of healthcare start-ups.

    Mirren is a trained surgeon with expertise in General Surgery and Plastics & Reconstructive Surgery, and held surgical posts at major teaching hospitals including University College Hospital, Royal Free Hospital and St George’s Hospital. He qualified as a doctor at St. George’s Medical School, University of London, and undertook research on innovative surgical technologies, including on virtual reality simulators and motion analysis, with Lord Ara Darzi at Imperial College, London. He is a Member of the Royal College of Surgeons of England and also received an MBA from London Business School.

  • Close

    Tyrone Mao

    Site Leader of Emerging Markets

    Tyrone Mao is Senior Director, Emerging Market R&D, Johnson & Johnson Consumer and the Site Leader of Emerging Market at Johnson & Johnson Innovation Centre, Asia Pacific. 

    Previously, Tyrone held the roles of Senior Director, Global Engineering – Asia Pacific, Johnson & Johnson Consumer and Regional Director, Packaging, J&J Consumer.  Prior to joining Johnson & Johnson, Tyrone was the Section Head of Oral Care R&D at the Proctor & Gamble Beijing Technical Center.

    Tyrone holds his M.S. in Polymer Science and his B.S. in Chemistry from Zhejiang University.

  • Close

    Thorsten Melcher,
    PhD

    Senior Director, New Ventures

    Thorsten is Senior Director for New Ventures Johnson & Johnson Innovation, California. He focuses on establishing and guiding collaborative partnerships with academic centers and biotech companies, and on facilitating new company formation by internal and external entrepreneurs.

    Previously, Thorsten led the biomedical efforts at Varian Medical Systems, an instrumentation and software company in radiation oncology. At Varian, he established a spin-out company to integrate radiotherapy with targeted cancer therapeutics. Before Varian, Thorsten was co-founder and was serving in several R&D, business development and operational and roles at AGY Therapeutics, EnVivo Pharmaceuticals and Saegis Pharmaceuticals. These California-based start-up companies focused on discovery and early development in various neurological and mental disorders. Thorsten’s scientific experience spans therapeutics in neuroscience and oncology, companion diagnostics and early clinical development. On the business side, he focuses on licensing and collaborative arrangements and private financings.

    Thorsten received his MS in Biochemistry from the University and Medical School in Hannover, Germany and his PhD in Molecular Neurobiology from the Center of Molecular Biology at the University of Heidelberg, Germany. He was a postdoctoral fellow at the University of California, San Francisco.

  • Close

    Anthony Milinowicz

    Director Digital Innovation

    Anthony is Director, Digital Innovation at Johnson & Johnson Innovation, California managing technology initiatives for the California Innovation Center, Johnson & Johnson Development Corporation and JLABS.

    Anthony has 14 years of technology experience within J&J and has worked in multiple sectors across the company. During that time he helped deliver cutting edge technology solutions for scientists, product development teams, and an internal venture designed to create technology based products for Johnson & Johnson.

    Anthony earned a Bachelor of Science in Computer Engineering from Lehigh University and an MBA from The Wharton School of the University of Pennsylvania. He also holds a patent for an Energized Biomedical Device in the RFID technology space.

  • Close

    Laurent Morlet,
    PhD

    Director, Digital Health New Ventures

    Laurent is Director Digital Health New Ventures at Johnson & Johnson Innovation, London where he is responsible for driving J&J Innovation digital health strategy through the identification and development of investment opportunities in EMEA.

    Prior to his joining J&J Innovation, Laurent spent 12 years in J&J, within clinical R&D and clinical IT delivering innovative technology based solutions supporting clinical trials.

    Laurent started his career as a research scientist specializing in photodynamic therapy, an innovative approach in oncology, before joining a virtual biopharmaceutical company in a business development role to evaluate in-licensing and M&A opportunities.

    Laurent holds a PharmD from the University of Nantes and postgraduate specializations in photobiology and drug delivery systems.

  • Close

    Nick Mourlas,
    Ph. D.

    Senior Director, New Ventures


    Nick is Senior Director, New Ventures at Johnson & Johnson Innovation, California.  He focuses on medical device innovation in support of the general surgery, orthopedics, and cardiology businesses. His charge is to identify licensing, collaboration, and investment opportunities highly aligned with J&J business strategies by building relationships with entrepreneurs, venture investors, and key opinion leaders. 
     
    Previously he served as PARC's Director of Global Healthcare Innovation and as the Xerox Innovation Group’s Healthcare Program Manager. His focus was on developing and executing a high-impact innovation strategy that aligned with the long-term roadmap of the Xerox healthcare businesses by identifying and understanding emerging trends in healthcare and technology.
     
    Nick’s start-up experience includes founding companies in orthopedics, cardiology, and radiation oncology. He was the CEO of Tarsus Medical - acquired by Integra LifeSciences (IART), and Acumen Medical - acquired by Medtronic (MDT). 
     
    Dr. Mourlas holds a Ph.D. in Electrical Engineering from Stanford University where he was the John B. Simpson Biomedical Innovation Technology Fellow in the inaugural year of Stanford's Biodesign Fellowship Program. He also received his AB in Engineering Sciences from Dartmouth College, and a BE from Dartmouth’s Thayer School. He regularly guest lectures at Dartmouth College and Stanford on the topic of medical device innovation.
     

  • Close

    Widya Mulyasasmita,
    PhD

    Manager, New Ventures

    Widya joined Johnson & Johnson Innovation, California as part of the New Ventures team, supporting deals and collaborations across consumer, medical device and pharmaceutical sectors.

    Widya comes to Johnson & Johnson from McKinsey & Company, where she was a management consultant advising clients in healthcare and other industries on corporate strategy, lean operations, and organizational health topics. Prior to McKinsey, Widya worked at GE Ventures Healthcare as an Associate Intern, and she also co-founded a medical device startup called LapIQ, where she served as Chief Scientist developing biodegradable wound closure devices. 

    Widya is a bioengineer with expertise in biomaterials, drug delivery, and regenerative medicine. She received her B.S. in Materials Science Engineering and Bioengineering from the University of California Berkeley and her Ph.D. in Bioengineering from Stanford University where she was a Siebel Scholar.   

  • Close

    Vijay Murthy,
    PhD

    Principal, Venture Investments

    Vijay is a Principal of Venture Investments at Johnson & Johnson Innovation, JJDC. Inc. (JJDC) and is based in the Johnson & Johnson Innovation Center in California. Vijay focuses on venture investments in biotechnology, pharmaceuticals, and diagnostics.

    Prior to joining JJDC, Vijay was a Director of Ventures & Early-Stage Collaborations at AbbVie, where he focused on venture investments and preclinical business development transactions. Prior to AbbVie, Vijay was co-founder and CEO of an early-stage peptide manufacturing company, and an independent consultant to several top-tier life sciences venture capital firms and biopharmaceutical companies. Previously, Vijay led business development at Enlight Biosciences, a seed-stage venture creation firm founded by PureTech Health and partnered with 7 major biopharmaceutical companies. He started his business career as a strategy consultant at the Boston Consulting Group (BCG).

    Vijay earned an AM and a PhD in biophysical chemistry from Harvard University, and a BS in chemistry with highest honors and highest distinction from the University of North Carolina at Chapel Hill.

  • Close

    Marian Nakada,
    PhD

    Vice President, Venture Investments

    Marian is a Vice President in Venture Investments at Johnson & Johnson Development Corporation, and is based in the Johnson & Johnson Innovation Center in Boston.  She focuses primarily on pharmaceuticals (small molecules and biologics) and diagnostics.

    Previously, Marian was Vice President of Strategy & Operations and External Innovation for Johnson & Johnson’s Biotechnology CoE, where she helped drive the development and execution of the biotechnology strategy across Janssen R & D. In her role as External Innovation lead, she nurtured many productive partnerships with external partners in the biotech industry and helped build an external innovation network to complement internal research and support the execution of the Janssen R&D Biologics strategy.

    Marian joined Centocor in 1990, as a scientist, performing basic research related to biologics for inflammatory and cardiovascular indications. In 2001, she took on the leadership of the newly formed Oncology Research group at Centocor. In 2007, Marian joined the Business Development group where she participated in executing technology licenses for the Johnson & Johnson pharmaceuticals group. In that role, she identified and championed external technology opportunities to ensure that Centocor's technologies were competitive with the industry.

    Marian has authored 62 peer reviewed publications and 14 book chapters and reviews. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania.

  • Close

    Shakti Narayan,
    PhD, JD

    Vice President,Transactions

    Shakti is Vice President, Head of Transactions at Johnson & Johnson Innovation, Boston.

    Previously, Shakti led Business Development at Nodality, a VC-backed personalized medicine biotechnology company developing predictive clinical diagnostics and more efficient drug development approaches in cancer and autoimmune disease.  Prior to that, he held positions in Business Development at Genentech, and he practiced life sciences transactional law at Wilson Sonsini Goodrich & Rosati.

    During his career, Shakti has led and closed multiple life sciences transactions, leveraging his interests and training in science, business and IP/contract law.  Shakti earned his BA degree in Biology from Grinnell College.  He earned a PhD in Cellular & Molecular Biology at the University of Wisconsin-Madison & the Salk Institute, and he was a post-doctoral scientist at Stanford University.  His legal studies were completed at the University of California- Berkeley Law School, where he earned a JD.

  • Close

    Kuldeep Neote,
    PhD

    Senior Director, New Ventures

    Kuldeep is Senior Director of New Ventures at the Johnson & Johnson Innovation, Boston. He focuses primarily on the areas of Oncology and Immunology.

    A trained molecular biologist with an extensive background in drug discovery, Kuldeep has been focused on the areas of Immunology, Inflammation and Oncology and has a passion for implementing cutting edge scientific discoveries into practical drug discovery programs.

    Formerly, Kuldeep was Research Advisor/Director in Global External R&D at Eli Lilly.    Prior to Eli Lilly, he was a Discovery Scientist at Pfizer, where he initiated the chemokine receptor drug discovery platform that led to the discovery and further development of several clinical candidates.  Earlier in his career, Kuldeep also cloned one of the first chemokine receptors while at Genentech.

    Kuldeep earned his BSc. in Microbial and Cellular Biology at the University of Calgary, and a PhD in Human and Molecule Genetics at the University of Toronto, where he was a major contributor in the understanding of the molecular basis of lysosomal storage diseases, in particular Tay Sachs and Sandhoff’s disease.

  • Close

    Jeffrey S. Nye,
    MD, PhD

    Vice President Neuroscience Innovation and Scientific Partnership Strategy

    Jeff is Vice President of Neuroscience Innovation and Scientific Partnership Strategy at the Johnson & Johnson Innovation, Boston. Jeff is responsible for external R&D in neuroscience, focusing on novel business relationships, venture, academic, public-private partnerships and risk-shared outsourcing.

    Previously, Jeff was Chief Medical Officer of the East Coast Research and Early Development unit and was responsible for early programs across all therapeutic areas.  Prior roles include VP of Experimental Medicine, and leader of programs for Galantamine for Alzheimer’s disease, and Topamax for epilepsy and migraine.  He previously served as a Director of CNS Discovery Genomics and Biotechnology at Pharmacia.

    Prior to joining industry, Jeff was a tenured associate professor of Molecular Pharmacology, Biological Chemistry and Pediatrics (Neurology) at Northwestern University.  He has a BA and MA from Harvard, and a MD and PhD (with Solomon Snyder) from the Johns Hopkins University School of Medicine.  He served as resident, postdoctoral fellow (with Richard Axel) and assistant professor of Pediatrics in Neurology at the College of Physicians and Surgeons of Columbia University.

    Jeff has published over 60 papers on basic and clinical research, and has led pharma programs in discovery through clinical development.  He has served on study sections and advisory panels, and currently serves as a Councilor of the British Association of Psychopharmacology, Advisory panel for the Allen Institute, and the co-chair of the New York Academy Alzheimer’s Leadership council.

  • Close

    Scott Orchard,
    JD

    Senior Counsel

    Scott is Senior Counsel at Johnson & Johnson Innovation, Boston where he is engaged in the full range of strategic transactions, including options to license or acquire technology, collaborations and licenses, sponsored research and venture capital investments.

    Previously, Scott was employed by several major New England based law firms and as an in house lawyer at a publicly traded manufacturing company. In those capacities, Scott advised public and private companies and private equity and venture capital firms on mergers and acquisitions, equity and debt financings, restructurings and other strategic and commercial transactions. Scott also has extensive experience counseling early stage companies and angel investors.

    Scott graduated from the University of Virginia School of Law and the University of California at Berkeley. Prior to law school Scott was an aide to U.S Senator William V. Roth, Jr. and a financial analyst in the investment banking division of Morgan Stanley & Co., Inc.

  • Close

    Sonal Patel,
    PhD

    VP, Oncology Scientific Innovation

    Sonal is VP of Oncology Scientific innovation at Johnson & Johnson Innovation, London.  In this role Sonal uses her drug discovery and scientific experience to identify and lead external opportunities in the Oncology therapeutic area.

    Prior to joining Johnson & Johnson, Sonal has experience in 2 previous pharma companies, as Senior Director, External Innovation at the Roche Innovation Centre in Basel, Switzerland, and as Head of Disease Biology in the Bioelectronic Medicines R&D unit of Glaxo SmithKline in Stevenage, UK.  In both roles Sonal Led scientific diligence of new opportunities across therapeutic modalities including devices and led partnerships to develop a portfolio of external collaborations for pharma.

    Sonal has had an extensive prior career in biotech in the UK as Head of Molecular Pharmacology at Prosidion-OSI, working on diabetes and obesity drug targets,  Oncology leader for  a start-up, Piramed Ltd on small molecule discovery for PI3K family and at Oxford Glycosciences, a proteomics platform company, leading  target Identification and validation for oncology discovery projects.

    Sonal completed postdoctoral training at the Lombardi Cancer Centre, Dept. of Radiation Medicine  at Georgetown University working on the downstream mediators of raf-1 kinase signaling  in cancer and received her PhD from the University of Bradford, Institute of Cancer Therapeutics  on the Immuo-modulatory mechanism of the anticancer agent 5,6-DMXAA and it analogues.

  • Close

    Charles R. Bridges,
    MD, Sc.D.

    Vice President, Therapeutic Area Expert, CV

    Charles R. Bridges is the Vice President, Therapeutic Area Expert Cardiovascular for Medical Devices.  In this role, he accelerates innovation, and advances the standard of care within early stage science to elevate existing and adjacent technologies. 

    Charles is a board certified cardiothoracic surgeon and is an internationally-recognized expert in cardiovascular gene therapy, blood conservation and transfusion-free cardiac surgery.  He is responsible for identifying new technology platforms for cardiovascular that provide transformational innovation. 

    Charles joined Johnson & Johnson Innovation from Carolinas Healthcare System, where he was Chairman of the Department of Thoracic and Cardiovascular Surgery and Vice President of Cardiovascular Translational Research. He was previously Professor of Surgery at the University of Pennsylvania and Chief of Cardiac Surgery at Pennsylvania Hospital. A distinguished surgeon-scientist, he invented the concept of “molecular cardiac surgery.”  

    Charles has received more than $10M in NIH funding and has over 160 peer-reviewed publications, twelve issued and pending U.S. and international patents for inventions in the fields of cardiovascular devices and cardiac and systemic gene and cell delivery.  He has served as a consultant to the Circulatory System Devices Panel of the U.S. Food and Drug Administration and as a regular member of the Bioengineering, Technology and Surgical Sciences Study Section of NIH.  He currently serves as a member of the Steering Committee of the Gene Therapy Resource Program (GTRP) of the National Heart Lung and Blood Institute, and as Chairman of the Cardiovascular Committee of the American Society for Cell and Gene Therapy.

    Charles received an A.B. in Applied Physics from Harvard College magna cum laude at age 19 and an M.D. from Harvard Medical School in the Harvard-M.I.T. Program in Health Sciences and Technology.  He received a Master of Science in Electrical Engineering and Computer Science and a Doctor of Science in Chemical Engineering from M.I.T. where he was elected to Sigma Xi as a Whittaker Health Sciences Fellow.  He competed in the 2016 World (Rubik’s) Cube Association US Nationals competition. 

  • Close

    Robert Radinsky,
    PhD

    Vice President, Scientific Innovation

    Robert Radinsky, Ph.D. is Vice President, Scientific Innovation at Janssen Research & Development, LLC. He represents the Oncology Therapeutic Area in Johnson & Johnson Innovation, Boston. In this role, he is responsible for identifying and fostering innovation that supports the Oncology Therapeutic Area strategies. Prior to this role, he led Discovery Research, Oncology Therapeutic Area, for Janssen Research & Development.

    Robert has had a very successful oncology research career in both academics and industry. Prior to joining Janssen, he was Executive Director, Oncology Research at Amgen Inc., where he led groups at multiple research sites including Thousand Oaks, California, and Cambridge, Massachusetts. He was responsible, in part, for research and/or pharmacology for numerous active targeted therapeutic anti-cancer programs (protein, small molecule and nanotechnology modalities), culminating with multiple candidates in clinical trials and an approved drug for the treatment of colorectal carcinoma.

    Before joining the industry 15 years ago, Robert was on the faculty at The University of Texas MD Anderson Cancer Center in Houston, first serving as an American Cancer Society Postdoctoral Research Fellow in the Department of Cell Biology, and eventually becoming a tenured Associate Professor in the Department of Cancer Biology. He continued as an Adjunct Professor at the MD Anderson Cancer Center after joining the industry.

    Robert has published more than 135 peer-reviewed articles, holds multiple patents, and is a present/past member of numerous societies, including the American Association for Cancer Research, Board of Directors for the Metastasis Research Society, the American Association for the Advancement of Science, the Scientific Advisory Board and the Aspen Cancer Conference. He is an Editorial Member and/or ad hoc reviewer for more than 20 scientific journals and has served on review panels for a number of granting agencies, including the National Institutes of Health/National Cancer Institute, the Department of Defense Prostate and Breast Cancer Research Programs, and the Veterans Administration Merit Review Board.

    Robert earned his doctorate in Molecular Biology and Microbiology from Case Western Reserve University School of Medicine in Cleveland, Ohio and Bachelor of Science degree in Cell and Developmental Biology from Purdue University in West Lafayette, Indiana.

  • Close

    Melinda Richter

    Head of JLABS, Johnson & Johnson Innovation

    As Head of JLABS, Melinda fosters Johnson & Johnson’s external R&D engine and supports the innovation community by creating capital-efficient commercialization models that give early stage companies a big company advantage. By providing infrastructure, services, educational programs and networks in global hotspots, JLABS is the best place to start a biotech company.

    Prior to joining JLABS, Melinda was Founder and CEO of Prescience International, an award winning firm dedicated to accelerating research to the patient. Melinda founded Prescience after she had a medical emergency that left her questioning the efficiency and efficacy of the healthcare system. With the tenacity and resolve of a patient looking for a better solution, she set-out to create a better model, which now forms the basis for JLABS’ operational infrastructure.

    Prior to starting Prescience, Melinda held posts across a variety of functional areas with a global corporation, Nortel Networks, in locations such as Research Triangle Park, New York, Toronto, London, Hong Kong and Beijing before arriving in San Francisco. She also started, raised capital and did large corporate deals for several companies in both the life science and technology space. She holds a Bachelor of Commerce from the University of Saskatchewan in Canada and an MBA from INSEAD in France.

  • Close

    Stephanie Robertson

    Director, New Ventures

    Stephanie joined the New Ventures team at J&J’s California Innovation Center in 2014. She brings expertise in drug discovery and early clinical development, as well as business development and alliance management.

    Previously, Stephanie was at the University of California, San Francisco UCSF where she led business development efforts for the campus and built and led a one of the first formal alliance management teams found in an academic setting. Prior to this, Stephanie was Program Director for the UCSF Sandler Center for Drug Discovery and also helped in the establishment and oversight of the UCSF Grand Multiple Myeloma Translational Initiative (GMMTI). Prior to joining UCSF, Dr. Robertson worked for over a decade at Exelixis, Inc. During her tenure at Exelixis the company grew from early start-up to over 700 employees. She grew from leading a computational biology team to serving as scientific project leader for drug discovery programs in cancer, cardiovascular disease and metabolism, project manager for early oncology clinical programs and leading alliance management for several programmatic collaborations with large pharma.

    She earned an undergraduate degree in chemistry (Honors) at the University of Michigan, Ann Arbor, and a Ph.D. in chemistry at the University of California, Berkeley.

  • Close

    Bruce R. Rosengard,
    MD, FRCS

    Chief Medical Science and Technology Officer

    Bruce R. Rosengard is the Chief Medical Science and Technology Officer for Johnson & Johnson Medical Devices Companies.   In this role, he is responsible for creating and delivering on a future oriented, strategic, and relevant medical innovation strategy.  Bruce and his team will identify emerging surgical trends and novel technology platforms with the goal of bringing innovative device solutions in the surgical and interventional spaces into the Medical Devices portfolio.
     

    A cardiothoracic surgeon and NIH-funded scientist, Dr. Rosengard, previously served as Vice President, New Business Ventures for The Medicines Company, where he played a pivotal role in several major acquisitions that have expanded the Medicines Company’s Surgical and Perioperative Care franchise.  Before joining The Medicines Company, Bruce was the Surgical Director of Cardiac Transplantation at Massachusetts General Hospital and on the faculty of Harvard Medical School.  In addition to leading the clinical program, he ran an NIH-funded laboratory in transplantation immunology.  Prior to this, Dr. Rosengard was the inaugural British Heart Foundation Professor and Chairman at the University of Cambridge, where he pioneered “beating heart” transplantation.  Bruce started his career at The University of Pennsylvania, where he performed the first combined heart-lung transplant at the institution, described a novel cellular mechanism responsible for triggering of transplant rejection, and patented a stem cell-based therapy to treat congestive heart failure.

     

    Bruce was graduated summa cum laude from Tufts University with a double major in Biology and Chemistry.  He obtained his MD degree from John Hopkins, where he also completed his postgraduate training in general surgery, cardiothoracic surgery, and surgical critical care.  During his training, he also completed a two-year postgraduate fellowship in transplantation immunology at the National Cancer Institute.  Bruce has authored more than 80 peer-reviewed publications, has given more than 40 invited talks at national or international meetings, and has served on the Boards of several professional societies.

  • Close

    Giridhar Sathiamoorthy

    Director of Business Operations and Project Management

    Giridhar Sathiamoorthy (Giri) is the Director of Business Operations and Project Management and is based in Singapore. 

    Prior to joining Johnson & Johnson, Giri worked with GE Healthcare, Unilever (India), and Tyco International in the US. Giri joined Johnson & Johnson in 2008 where he was a part of the International Recruitment and Development Program at Johnson & Johnson Medical India. Giri transitioned to the regional Business Knowledge Centre and established the business analytics function for the orthopedic business in Asia-Pacific. In 2012, he took on the additional responsibility as the PMO lead for DePuy Synthes integration. Giri also led the Strategic Planning function for the newly formed Global Orthopedic Group in the region. 

    Giri received his MBA from Thunderbird School of Global Management, and a Masters in Chemical Engineering from Florida State University.

  • Close

    Eric Schaeffer

    Senior Director, Neuroscience Innovation

    Eric is Senior Director of Neuroscience Innovation at the Johnson & Johnson Innovation Center, Boston.  Eric has more than 23 years of drug discovery and development experience with an extensive background in the biology and pharmacology of CNS disorders.

    Previously Eric was Director of Neuroscience Clinical Biomarkers at Bristol-Myers Squibb where he was responsible for developing the translational strategies for early clinical programs in the areas of schizophrenia, depression and neuromuscular diseases.  Other previous roles held by Eric include Senior Director of Neuroscience Discovery at Pfizer where he was responsible for leading preclinical pharmacology teams and Director of Neuropharmacology at CHDI where he was responsible for initiating and managing biotech and academic partnerships focused on Huntington’s disease.

    Eric received a BA in Biology from Colgate University and a PhD in Molecular Biology from the Albert Einstein College of Medicine.  He went on to do postdoctoral fellowships at the Massachusetts Institute of Technology and Rockefeller University prior to initiating a career in the pharmaceutical industry.

  • Close

    Nerida Scott

    Senior Director, Transactions

    Nerida is the Senior Director for Transactions, at Johnson & Johnson Innovation, London.

    Nerida has over 15 years’ experience within the pharmaceutical sector. Before joining the Johnson & Johnson family, Nerida was the Business Development & Licensing Director and Executive team member at Vernalis PLC. In this position, she was responsible for leading transactions from their evaluations through to negotiation and closing. She has experience in licensing and collaboration transactions, as well as acquisitions and divestments.  Previous experience includes business development at RiboTargets and Project Leader at The Boston Consulting Group in London where she provided strategic advice to the Pharma clients on M&A opportunities, R&D and manufacturing business functions. Nerida brings a broad and extensive background in operational and commercial activities in the R&D sector in both the US and the UK.

    Nerida received her BSc from Sydney University and her PhD. in Biochemistry from Cambridge University. 

  • Close

    Guy Seabrook,
    PhD

    Vice President, Neuroscience Innovation

    Guy is Vice President of Neuroscience Scientific Innovation at Johnson & Johnson Innovation, California.   Guy has more than 23 years of drug discovery research experience, which includes preclinical research on marketed products and candidates in clinical development.

    Formerly, Guy was part of Eli Lilly’s Global External Research & Development organization where he led the the GER&D team for the Lilly Bio-Medicines Business Unit, and also at Merck & Co, Inc where he was the Head of the West Point Department of Alzheimer's Disease Research.

    Guy graduated with a PhD in Zoology from the University of Nottingham UK, and completed his postdoctoral research at the University of Miami School of Medicine USA.

  • Close

    Nikie Shi,
    MBA

    Director, Transactions

    Nikie Shi is The Director Transactions at Innovation Center, Asia Pacific.  She has past experience in all aspects of the deal processes and has extensive experience in developing strategy and executing transactions in collaboration with multi-disciplinary teams.

    Previously, Nikie was an Executive Director at Ernst & Young and a Managing Director at Ivylink Partners. In these roles, she has advised health care and consumer clients in their M&A strategy and deal executions in China.  Her key clients included Pfizer, BMS, Johnson & Johnson, Life Tech.  Prior to that, Nikie worked in investment banking at Morgan Stanley in New York and investment management at Alliance Capital (now known as Alliance Bernstein) in London.  Through her 8 years of work, Nikie has built a strong network with the health care community, including entrepreneurs, investors, academic institutions and government agencies.

    Nikie received her BS from Peking University in China and MBA from the University of Chicago.

  • Close

    Kenny Simmen,
    PhD

    Vice President, Infectious Diseases and Vaccines Scientific Innovation

    Kenny is Vice President of Infectious Diseases and Vaccines Scientific Innovation at Johnson & Johnson Innovation, London.

    He has overseen the drug discovery and progression of multiple compounds from the bench to clinical proof-of-concept, particularly for the treatment of chronic hepatitis C virus (HCV), including Simeprevir (TMC435). Other assets that have been advanced in the portfolio address medical needs in HIV, influenza and other respiratory infections.

    Kenny joined the Johnson & Johnson Family of Companies in 1997, initially in the Pharmaceutical Research & Development group in La Jolla, California, and then moving to Belgium to join the newly-acquired Tibotec in 2002 to lead HCV research.

    Kenny holds an BSc (Hons) degree in Molecular Biology from the University of Edinburgh, Scotland, and obtained his PhD at the European Molecular Biology Laboratory (EMBL), Heidelberg.  He trained as a postdoc (EMBO and HFSP Fellowships) with Prof Bernards at the Netherlands Cancer Institute in Amsterdam on viral transcription factors, before entering the pharmaceutical industry with Roche UK, where he worked on antiviral drug discovery against herpes viruses. 

  • Close

    Peter Stebbins

    Transactions Lead, Medical Devices

    Peter is Transactions Lead, Medical Devices, based at the Johnson & Johnson Innovation Center, Boston.  In this role, he provides deal leadership in partnering with early stage companies across the medical device sectors. 

    Peter has been with J&J since a business school internship in 1990.  He joined the JJIC in November 2016.  His previous position was Vice President of Strategy for DePuy Synthes Orthopedics and Business Development for Codman Neuro.   Prior to that, Peter held a series of VP positions in Marketing, Strategic Marketing and Business Development for Mitek Sports Medicine and Codman Neuro.  He helped reposition Mitek from purely shoulder anchors to arthroscopy enabling solutions and to earlier intervention, exemplified by Orthovisc and Monovisc HA injections for OA.  At Codman Neuro, he helped redefine their business by divesting the Instruments business unit and emphasizing neurovascular stroke intervention, exemplified by Micrus and Pulsar.

    Before his stints in Ortho and Neuro, Peter spent the first half of his career in the Ethicon Surgery businesses, starting in Operations before going into Field Sales and into Marketing, including working in Scotland as Director of European Marketing for Ethicon.

    Peter studied Chemical Engineering at Princeton on an ROTC scholarship before serving with US Army Forces in West Germany and attending Harvard Business School.

     

  • Close

    Lesley Stolz,
    PhD

    Head of JLABS California

    Lesley is the Head of Johnson & Johnson Innovation, JLABS Caifornia.

    Formerly, Lesley served as the Senior Director of Transactions where she was instrumental in constructing many deals for the California Innovation Center, which included the expansion of JLABS to Houston and Toronto. 
     
    Before joining the Johnson & Johnson Innovation family, Lesley spent 18 years in business and corporate development positions in biotechnology companies, most recently as Vice President Business Development for Sutro Biopharma and BioTime.  Lesley also spent four and a half years in Munich, Germany working in business development for the German biotechnology company, GPC Biotech.  
     
    Lesley received a Bachelor of Science in Chemistry from the University of Virginia and a Master of Science and Ph.D. in Chemistry from the University of Rochester.  For her post-doctoral research, Lesley shifted to biochemistry and enzymology at Harvard Medical School.  

  • Close

    Jim Tobin,
    PhD

    Vice President, Cardiovascular & Metabolic Scientific Innovation

    Jim is the Vice President of Cardiovascular & Metabolic Scientific Innovation at Johnson & Johnson Innovation, Boston.  He has over 19 years of drug development experience in the areas of hemostasis, inflammation, muscle degenerative diseases, and diabetes.

    Most recently, Jim was an entrepreneur-in-residence at Atlas Venture and focused on company formation in the life science sector.

    Prior to joining Atlas, Jim held the position of Vice President and Chief Scientific Officer at Pfizer leading a research unit focused on the development of biologics for the treatment of metabolic diseases and hemophilia.  Prior to that he held the role of Vice President of Cardiovascular and Metabolic Diseases at Wyeth Pharmaceuticals and led the metabolic disease group with a focus on both small molecule and protein therapeutics in type 2 diabetes and muscle disease.  Under Jim’s direction these groups advanced over 15 biologics and small molecules into clinical development.

    Jim began his career at Genetics Institute (GI) where he was part of the structure based drug discovery group and was involved in the research and development of a number of biopharmaceutical products in inflammation, transplantation and thrombocytopenia, including the marketed product Neumega.

    Jim obtained his PhD in Biochemistry from Brandeis University and completed his NRSA postdoctoral fellowship at Harvard University.  He has authored 50 publications in peer-reviewed journals and is the inventor on 10 patents.

  • Close

    Sanjay Vinaik,
    CPA, CMA, ACA

    Senior Director, Business Operations & Program Management

    Sanjay is Senior Director of Business Operations & Program Management at the Johnson & Johnson Innovation, Boston.  In his role, he provides business operations and program management support for the innovation center in Boston, as well as to broader Johnson & Johnson Innovation counterparts.

    Sanjay has extensive experience in various roles in the Alliance Management, Global Strategic Marketing, L&A and Finance functions at the Pharmaceutical, Medical Devices & Consumer companies of Johnson & Johnson in the U.S. and abroad.

  • Close

    Erin Washington

    Manager, Transactions & Business Analytics

    Erin is a Manager at the Boston Innovation Center. She is responsible for leading and executing deals across pharmaceuticals, medical devices, and consumer products.

    Prior to joining Johnson & Johnson, Erin was an Associate at Leerink Swann Consulting, where she advised on business development and corporate strategy for life sciences clients.

    Erin holds a BA in Organismic and Evolutionary Biology from Harvard University. 

  • Close

    Stuart Wilks,
    JD

    Assistant General Counsel

    Stuart is Assistant General Counsel at Johnson & Johnson Innovation, California.

    Stuart has supported a diverse group of Johnson & Johnson operating companies and units, such as Alza, BabyCenter, Janssen Health Innovation, Janssen Research & Development, Janssen Supply Chain, Johnson & Johnson Development Corporation, Noramco, and Scios in a broad range of business and contractual matters.

    Formerly, Stuart was corporate counsel at Scios, Inc. in Fremont, California and corporate counsel at COR Therapeutics, Inc. in South San Francisco, California.  Stuart moved to Silicon Valley in 1996 and was an associate in the corporate and life sciences practice groups of the Palo Alto office of Cooley LLP. 

    Stuart received his BA in chemistry at Yale University, and a JD from the University of Chicago.

  • Close

    Eric Wu

    Senior Counsel

    As a member of the Business Development Law Group, Eric has responsibilities for the Business Development activities across the AsiaPac Region for the Consumer, Medical Device and Pharmaceutical Groups. Eric provides support to the AsiaPac Innovation Center located in Shanghai. 

     

    Eric was previously with Jovian Petroleum Corporation, where he was Vice President/Associate General Counsel responsible for M&A as well as general corporate and litigation activities. Prior to his role at Jovian, Eric was a Senior Associate at Ropes & Gray, LLP, Shanghai, where he had a broad life-science practice advising early-stage venture capital backed companies as well as private equity and venture capital funds. Eric first worked in Shanghai as an Associate at Skadden, Arps, Slate, Meagher & Flom, LLP, where he focused on complex cross-border transactions including acquisitions, divestitures and private equity transactions.

     

    Eric did his undergraduate work at Georgetown University and earned his J.D. from Boston University School of Law. Eric is admitted to the Bar in the Commonwealth of Massachusetts. Eric is fluent in Mandarin Chinese and English.  

  • Close

    Asish K. Xavier,
    PhD, MBA

    Vice President, Venture Investments

    Asish is with Johnson & Johnson Development Corporation (JJDC) and is based in the Johnson & Johnson Innovation Center in California.  Asish focuses on venture investments in biotechnology and diagnostics.  Asish joined JJDC in 2004, and has invested in over a dozen biotech and diagnostics deals.

    Asish previously worked in business development at BioRexis Pharmaceutical Corporation which was acquired by Pfizer in 2007.  While at BioRexis, he assisted the company in raising a $30 million second round of financing.  Asish has worked in business development at Structural GenomiX, Inc., acquired by Eli Lilly in 2008, and was a project leader at Message Pharmaceuticals, Inc.

    Asish received a PhD from the University of Houston in Chemical Engineering, and a MBA from the Wharton School of the University of Pennsylvania, where he graduated with honors.  He received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India.  Asish was a postdoctoral research Fellow in the Department of Chemistry at Johns Hopkins University.

  • Close

    Mingde Xia,
    PhD

    Senior Director, New Ventures

    Mingde is Senior Director of New Ventures at Johnson & Johnson Innovation, Asia-Pacific focusing on establishing collaborations across all three of our sectors.

    Mingde joined Johnson & Johnson in 1999 and worked as a project leader across many of our collaborations. He is an inventor or author of more than 60 patents and publications.

    Mingde earned PhD from Michigan Tech. He has actively involved in Sino-American Pharmaceutical Professionals Association and is a guest/adjunct professor at the Chinese Academy of Sciences. 

  • Close

    Hong Xin,
    PhD, MBA

    Director, New Ventures Greater China and Korea

    Hong is the Director of New Ventures, Greater China and Korea at the Innovation Center, Asia Pacific.  In this role, Hong is responsible for implementing the Asia Pacific Innovation Centre’s strategy in Greater China and Korea.

    Previously, Hong spent thirteen years as a drug discovery scientist within the Discovery Science organization of Janssen R&D in North America. Hong has extensive knowledge in drug discovery in various therapeutic areas and their associated novel platform technologies, and understanding of consumer business. Hong has broad discovery experience in various therapeutic areas, such as oncology, CVM, neuroscience, pain, and immunology. 

    Hong received her M.S. and Ph.D. degrees in Biochemistry from New York University, her MBA in Entrepreneurship & Innovation, and Leadership & Change Management from Leonard N. Stern School of Business, NYU. 

  • Close

    Rebecca Yu

    Head of JLABS @ Toronto

    Rebecca Yu is the Head of JLABS @ Toronto, Johnson & Johnson Innovation’s first JLABS incubator outside of the United States. JLABS @ Toronto is a partnership with Johnson & Johnson Innovation, Janssen Canada, the University of Toronto, MaRS Discovery District, MaRS Innovation and the Government of Ontario. Rebecca is responsible for overseeing and managing the business of JLABS @ Toronto including setting its strategic direction. As the local J&J Innovation ambassador to the life science innovation community in Ontario, Rebecca will be catalyzing and supporting the translation of science and technology into valuable solutions for patients and consumers across J&J's sectors in pharma, medical devices and consumer healthcare.

    Before assuming her current responsibilities at JLABS @ Toronto, Rebecca was Director, Strategic Health Technology Assessment (HTA) in the Government Affairs & Market Access with Janssen Canada. Rebecca spent 15 years in Health Policy, Medical Affairs, and Government Affairs with Solvay Pharma, Procter & Gamble, Servier and Pfizer. Prior to joining industry, she practiced as a Clinical Pharmacist at The Wellesley Hospital.

    Rebecca is a graduate of the University of Toronto, Faculty of Pharmacy and is currently a pharmacist in Ontario. Rebecca was previously on the Board of Directors for the Markham Stouffville Hospital. She is currently a member of the Joint Steering Committee for the Neuroscience Catalyst Collaboration and on the Life Sciences Ontario’s Board of Directors.

  • Close

    Wei Zang

    IT Lead

    Zhang Wei is responsible for supporting the information technology needs of the Asia Pacific Innovation center.  He focuses on operational and business intelligence systems such as CRM as well as ensuring that we are maximizing the use of technology to drive the business development activities of the APIC.

     

    Prior to his joining J&J Innovation, Wei has had roles of increasing management and systems responsibility with Shanghai ChanceShare Pharmacy Consulting Co., Ltd. and Unilever China. 

     

    Wei has a BS in Computer Science with Information Engineering from Hefei Industry University and a Master’s Degree in software engineering from Fudan University.  He will be based in the Shanghai together with Asia Pacific Innovation Center team. Wei will be part of the Digital Innovation team.

  • Close

    Biao Zheng

    Vice President, Immunology Scientific Innovation

    Dr. Biao Zheng, Vice President, Scientific Innovation Immunology. Biao is responsible for the creation and implementation of the external innovation plan to deliver on the Immunology TA strategy for the Asia Pacific region. Biao works to identify the best opportunities for value-generating collaborations and develop an industry-leading portfolio of investment opportunities as well as build and cultivate Janssen’s strong scientific reputation and a network of experts in the global innovation community.

     

    Prior to joining J&J, Biao was a professor at the Institute of Biomedical Sciences, East China Normal University. Prior to ECNU, Biao worked in GlaxoSmithKline R&D Center China, where he served as Head, Immunological Discovery. Prior to GSK, Biao was with Baylor College of Medicine as a tenured associate professor in the department of immunology. Prior to that, he was a faculty member in the department of immunology at Duke University Medical Center, Durham, North Carolina.

     

    In addition to his rich experience in Immunology Scientific Innovation, Biao has also published or co-published more than 60 academic articles and has been a speaker at conferences in the US, Europe and China.

     

    Biao holds a Ph.D. in immunology from King’s college, University of London. Biao received his M.D. from Zhejiang University School of Medicine.

  • Close

    Larry Zhy

    Senior Director, Transactions

    Larry supports the transactions team of the Asia Pacific Innovation Center.

    Previously, Larry was Vice President of General Operation at Amgen-Betta Pharmaceuticals in Hangzhou, China and Vice President of Strategic Collaboration at Betta Pharmaceuticals. Prior to that he was Managing Director at Hina Investment Group, Director of Strategic Transaction and Business Development at Xian-Janssen Pharmaceutical, Senior Director of Business Development at Cerenis Therapeutics and Head of Licensing & Development Esperion Therapeutics, a division of Pfizer.

     

    Larry earned a BS in Biochemistry from Beijing University, a PhD in Biochemistry from Ohio State University and a MBA from University of Michigan Ross School of Business.

  • Close

    Carolyne Zimmermann,
    MBA

    Senior Director of Transactions


    Carolyne is a Senior Director of Transactions for Johnson & Johnson Innovation in, California. She joins  Johnson & Johnson Innovation from Novartis Pharmaceuticals where, for over 13 years, she held leadership roles in the Global BD&L group and gained extensive experience in structuring and negotiating strategic transactions with both pharma and biotech entities, including collaborations, licensing deals, acquisitions and equity investments. 
     
    In her most recent role, Carolyne was as a General Partner to dRx Capital a $100mn venture fund founded in 2015 by Novartis and Qualcomm Ventures focused on early stage digital health investing. Prior to this, she led the Business Development and Licensing efforts for the Global Cardio-Metabolic Franchise where she was responsible for driving the external strategy and securing strategic assets to expand the portfolio. During her tenure at Novartis, Carolyne also led transactions and alliances in the areas of Respiratory, Immunology, Tropical Diseases and Digital Medicine.
     
    Carolyne earned her BS degree in Engineering Sciences from the University of California, San Diego and her MBA from Columbia Business School in New York.
     

Approach

Johnson & Johnson Innovation Centers bring forth a new model for advancing early-stage innovation, providing essential resources to meet the needs of life science entrepreneurs. 

A Global Team of Experts

Each regional Innovation Center houses science and business experts specialized in accelerating cutting-edge science into viable healthcare solutions with potential to improve lives around the world. 

Teams include veteran R&D and product development leaders, experienced investors, transaction and legal advisors and professionals from across finance and business development. 

We work side-by-side with innovators throughout their journey, providing a robust exchange of ideas and resources to support their success. 

Unique Collaboration 

Johnson & Johnson Innovation Centers are designed to provide entrepreneurs and scientists one-stop access to the broad resources of the Johnson & Johnson Family of Companies. 

Our method is to first understand our partners’ approach and what will be required to transform a promising idea into a real, tangible healthcare solution. To every conversation, we bring a strong history of success in R&D, product development, and commercialization. We work with companies in the earliest stages of innovation all the way up to and including proof-of-concept objectives.

The Tools You Need 

Johnson & Johnson Innovation Centers offer a diverse array of tools to advance new technologies and contribute to the success of our partner companies.

Depending on the stage of the company or technology, we can provide early-stage research funding, seed funding and equity investments as well as licensing and R&D collaborations.

Additionally, we offer a wide range of facilities and operational support to help start-up companies thrive. This includes JLABS sites, regional incubators and a year-round curriculum focused on business development and drug development.

Guidance to Grow 

Our Innovation Center teams are active in their scientific communities and in the broader Johnson & Johnson Innovation community. Through our connections, partners can access mentorship and networking support, including help entering international markets, cross-sector experience, pricing and reimbursement, market testing and new company creation.

Focus Areas

Johnson & Johnson Innovation Centers have flexible deal-making capabilities to support the needs of early-stage life science, medical device, and consumer companies, as well as entrepreneurs and academic researchers with an innovative idea. We look forward to working with you, and together, improving healthcare and our innovation ecosystem around the world. 

CLICK a business area of interest below
  • Consumer
  • Medical Devices
  • Pharmaceuticals
  • Global Public Health
CLICK on a circle to see the areas we are targeting
  • Healthy Sleep Habits, Massage and Sensory Enrichment, Safe Bug Care Products, Environmental Skin Protection (Germs, Sun, Pollution), Ease of Use Solutions
    Baby Care
    Baby Care
  • Skin, Acne, Blackheads, Oily Skin, Aging Prevention, Environmental Protection, Sunscreen Compliance and Sensory Experience, Body hydration and skin barrier protection, Therapeutic Hair Care, Novel Hair Growth Solutions
    Beauty
    Beauty
  • Bug Bites, Burns, Cracked Skin, Instant, Long-Lasting Pain Relief, Infection Reduction, Protection, Accelerate & Monitoring Healing, Ease of Use Solutions
    Compromised skin
    Compromised skin
  • Novel Solutions for Feminine Hygiene, Fit and Comfort, Discretion, Health Sensing & Promoting
    Feminine Personal Care
    Feminine Personal Care
  • Enamel Repair, Microbial Control for Prevention of Oral Conditions, Functional Barriers for Tooth Protection, Whitening Technologies, Oral Health Sensing
    Oral Care
    Oral Care
  • Pain: Episodic and Recurrent Head and Body Pain,
    Cough & Cold: Multi-symptom Head Cold, Cough and Sore Throat,
    Digestive Health: IBS, Diarrhea, Constipation, Indigestion, Dehydration, Heartburn,
    Allergy: Episodic Respiratory, Skin/Atopic, and Food Allergies,
    Smoking Cessation: Nicotine replacement therapy, non-nicotine drugs, devices, behavioral programs
    OTC
    OTC

Contact us

Make the Connection

We look forward to our first discussion. If you would like to discuss a collaboration,
simply click the contact us button which will connect you to our Idea Portal and a member of our team will contact you.

contact

Accelerators

Close
Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
mail@www.neomed.ca
www.neomed.ca
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.